Page last updated: 2024-11-04

sk&f-38393

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine: A selective D1 dopamine receptor agonist used primarily as a research tool. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol : A benzazepine that is 2,3,4,5-tetrahydro-3-benzazepine bearing a phenyl substituent at position 1 and two hydroxy substituents at positions 7 and 8. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

SKF 38393 : A racemate comprising equimolar amounts of (R)- and (S)-SKF 38393 [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

(R)-SKF 38393 : A 1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol that is the R-enantiomer of SKF 38393. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID1242
CHEMBL ID286080
CHEBI ID110200
CHEBI ID131801
SCHEMBL ID469578
MeSH IDM0023985
PubMed CID147514
CHEMBL ID542700
SCHEMBL ID3425787
MeSH IDM0023985
PubMed CID6852376
CHEMBL ID24077
CHEBI ID125624
CHEBI ID131800
SCHEMBL ID7941051
MeSH IDM0023985

Synonyms (155)

Synonym
BRD-A88548664-001-02-3
gtpl935
r(+)skf38393
skf-38,393
skf-38393
sk&f-38393
brn 1543419
2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1h-3-benzazepine
1h-3-benzazepine-7,8-diol, 2,3,4,5-tetrahydro-1-phenyl-
sk&f 38393
2,3,4,5-tetrahydro-1-phenyl-1h-3-benzazepine-7,8-diol
LOPAC0_000436
PDSP2_001508
PDSP1_001524
skf 38393
BIOMOL-NT_000034 ,
NCGC00024875-04
NCGC00024875-02
SPECTRUM1505101
BSPBIO_002384
BPBIO1_001229
NCGC00024875-03
skf38393
67287-49-4
CHEBI:110200
NCGC00015299-06
CHEMBL286080 ,
sk-38393
ncg-c00093856-01
L000563
(+/-)-skf-38393
1-phenyl-2,3,4,5-tetrahydro-1h-benzo[d]azepine-7,8-diol; hydrochloride(skf 38393)
1-phenyl-2,3,4,5-tetrahydro-1h-benzo[d]azepine-7,8-diol
cid_147514
1-phenyl-2,3,4,5-tetrahydro-1h-benzo[d]azepine-7,8-diol (sk&f 38393)
bdbm50004923
1-phenyl-2,3,4,5-tetrahydro-1h-benzo[d]azepine-7,8-diol(skf 38393)
rs(+/-)skf 383931-phenyl-2,3,4,5-tetrahydro-1h-benzo[d]azepine-7,8-diol
5-phenyl-2,3,4,5-tetrahydro-1h-3-benzazepine-7,8-diol
CHEBI:131801
1-phenyl-2,3,4,5-tetrahydro-1h-3-benzazepine-7,8-diol
CCG-204528
NCGC00015299-03
NCGC00015299-05
NCGC00015299-04
r7tf327s2c ,
5-21-05-00258 (beilstein handbook reference)
unii-r7tf327s2c
SCHEMBL469578
6-phenyl-4-azobicyclo[5.4.0]undeca-7,9,11-triene-9,10-diol
(a+/-)-skf-38393 hydrochloride
BCP16347
DTXSID10894836
(+/-)- skf 38393
67287-49-4 (free base)
skf-38393 free base
(+/-)-1-phenyl-2,3,4,5-tetrahydro-(1h)-3-benzazepine-7,8-diol
skf-38393, (+/-)-
Q7390598
BRD-A88548664-004-01-9
SDCCGSBI-0050421.P002
NCGC00015299-11
(+/-)-1-phenyl-2,3,4,5-tetrahydro-(1h)-3-benzazepine-7,8-diol; (+/-)-skf 38393; 2,3,4,5-tetrahydro-1-phenyl-1h-3-benzazepine-7,8-diol; 2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1h-3-benzazepine
()-1-phenyl-2,3,4,5-tetrahydro-(1h)-3-benzazepine-7,8-diol; ()-skf 38393; 2,3,4,5-tetrahydro-1-phenyl-1h-3-benzazepine-7,8-diol; 2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1h-3-benzazepine
AKOS040749511
skf 38393 hydrochloride
EU-0100436
(+/-)-skf-38393 hydrochloride, crystalline, >=98% (hplc)
nsc-320959
62717-42-4
nsc320959
smr000326792
MLS000859931
(+/-)-skf-38393 hydrochloride
(?)-skf-38393 hydrochloride
skf-38393 hydrochloride
NCGC00093856-01
skf 38393a
D-047
( inverted question mark)-skf-38393 hydrochloride
( inverted question mark)-1-phenyl-2,3,4,5-tetrahydro-(1h)-3-benzazepine-7,8-diol hydrochloride
81633-77-4
chembl542700 ,
2,3,4,5-tetrahydro-1-phenyl-1h-3-benzazepine-7,8-diol hydrochloride
unii-wiv5r2g7vp
nsc 320959
wiv5r2g7vp ,
1h-3-benzazepine-7,8-diol, 2,3,4,5-tetrahydro-1-phenyl-, hydrochloride
c16h17no2.hcl
AKOS016012197
LP00436
1-phenyl-2,3,4,5-tetrahydro-1h-3-benzazepine-7,8-diol hydrochloride
CCG-221740
tox21_500436
HY-12520A
CS-5354
skf 38393 (hydrochloride)
(y)-skf-38393 hydrochloride
NCGC00261121-01
SCHEMBL3425787
skf-38393a
1-phenyl-2,3,4,5-tetrahydro-1h-benzo[d]azepine-7,8-diol hydrochloride
AC-32754
( inverted exclamation marka)-skf38393 hydrochloride
(+/-)-1-phenyl-2,3,4,5-tetrahydro-(1h)-3-benzazepine-7,8-diol hydrochloride
SR-01000075378-1
sr-01000075378
EX-A3563
skf 38393 hcl
BCP28880
HB6111
62717-42-4 (hcl)
S7993
skf38393 hcl
(+/-)-1-phenyl-2,3,4-tetrahydro(1h)-3-benzapezine-7,8-diol hydrochloride
DTXSID20936175
skf-38393 hcl
AS-16874
( inverted exclamation marka)-skf-38393 hydrochloride
1h-3-benzazepine-7,8-diol, 2,3,4,5-tetrahydro-1-phenyl-, hydrochloride (1:1)
(+/-)-skf-38393 hydrochloride;skf-38393a
C75947
2-phenyl-4-azabicyclo[5.4.0]undeca-7,9,11-triene-9,10-diol
(+/-)-1-phenyl-2,3,4,5-tetrahydro-(1h)-3-benzazepine-7,8- diol hydrobromide
()-skf-38393 hydrochloride;skf-38393a
(+/-)-skf-38393 hydrochloride d1 dopamin e receptor
5-phenyl-2,3,4,5-tetrahydro-1h-3-benzazepine-7,8-diol;hydrochloride
skf-38393hydrochloride
1h-3-benzazepine-7,8-diol, 2,3,4,5-tetrahydro-1-phenyl-,?hydrochloride (1:1)
CHEBI:125624
sk-383933
sk&f-383933
CHEMBL24077 ,
bdbm50274530
(1r)-1-phenyl-2,3,4,5-tetrahydro-1h-benzo[d]azepine-7,8-diol hyrobromide
(r)-1-phenyl-2,3,4,5-tetrahydro-1h-benzo[d]azepine-7,8-diol
bdbm50004822
skf 38393 (+)
1-phenyl-2,3,4,5-tetrahydro-1h-benzo[d]azepine-7,8-diol(skf38393)
7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1h-benzo[d]azepinium(r(+)skf38393)
(r)-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1h-benzo[d]azepinium
r(+)skf 383931-phenyl-2,3,4,5-tetrahydro-1h-benzo[d]azepine-7,8-diol
(1r)-1-phenyl-2,3,4,5-tetrahydro-1h-3-benzazepine-7,8-diol
(r)-skf 38393
CHEBI:131800
(r)-skf-38393
(5r)-5-phenyl-2,3,4,5-tetrahydro-1h-3-benzazepine-7,8-diol
1h-3-benzazepine-7,8-diol, 2,3,4,5-tetrahydro-1-phenyl-, (1r)-
62751-59-1
SCHEMBL7941051
unii-yzc2y51nhj
(1r)-2,3,4,5-tetrahydro-1-phenyl-1h-3-benzazepine-7,8-diol
skf-38393, (r)-
YZC2Y51NHJ ,
r-(+)-skf 38393

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
"The present experiments were performed to investigate the effects of dopamine D1 receptor agonists given alone or in combination with dopamine D2 receptor agonists on body temperature in rats."( Hyperthermia induced by the dopamine D1 receptor agonist SK&F38393 in combination with the dopamine D2 receptor agonist talipexole in the rat.
Furukawa, T; Kimura, H; Matsumoto, S; Nagashima, M; Yamada, K, 1992
)
0.28
" Clonidine and the slightly alpha 1-selective agonist ST587, but not ST91, an alpha-agonist which does not readily cross the blood brain barrier, produced marked stimulation when combined with the selective D2 agonist quinpirole."( Alpha 1 (but not alpha 2)-adrenoceptor agonists in combination with the dopamine D2 agonist quinpirole produce locomotor stimulation in dopamine-depleted mice.
Edis, LE; Eshel, G; Jackson, DM; Kelder, D; Ross, SB, 1990
)
0.28
" Furthermore, the data indicate that in normal rats D-1 receptors are functionally relevant since D-1 agonists facilitate the expression of oral stereotyped behaviour after combination with a D-2 agonist."( Dopamine D-1 receptor agonists combined with the selective D-2 agonist quinpirole facilitate the expression of oral stereotyped behaviour in rats.
Arnt, J; Hyttel, J; Perregaard, J, 1987
)
0.27
" Unlike clozapine, neither the selective 5-HT2 receptor antagonist, ritanserin, nor the dopamine D2 receptor antagonists, haloperidol and remoxipride, caused locomotor activation when given alone or in combination with SKF38393."( Why does clozapine stimulate the motor activity of reserpine-pretreated rats when combined with a dopamine D1 receptor agonist?
Bengtsson, A; Jackson, DM; Malmberg, A; Mohell, N, 1995
)
0.29

Bioavailability

ExcerptReferenceRelevance
" Compared with fasting, bioavailability of fenoldopam was decreased significantly when administered with food: mean peak plasma fenoldopam level decreased from 26."( The effect of food on pharmacokinetics and pharmacodynamics of fenoldopam in class III heart failure.
Blanchett, DG; Boyle, DA; Corder, CN; Cyronak, MJ; Green, JA; Jarvis, RC; Kasmer, RJ; Nara, A; Pospisil, R, 1991
)
0.28
" Lack of oral bioavailability has limited its use in long-term therapy, however; levodopa and dopa conjugates which are orally absorbed and metabolized to the active form are under investigation."( Dopamine and dopamine receptor agonists in cardiovascular therapy.
Elliott, WJ; Murphy, MB, 1990
)
0.28

Dosage Studied

ExcerptRelevanceReference
" After acquisition of the discrimination, the dose-response function for SKF (2."( Effects of chronic SCH 23390 or acute EEDQ on the discriminative stimulus effects of SKF 38393.
Cao, GH; Perry, BD; Woolverton, WL, 1992
)
0.28
" The increase in ERPF was not maintained to the end of the dosing interval during chronic administration, probably due to the short half-life of fenoldopam."( Fenoldopam reverses cyclosporine-induced renal vasoconstriction in kidney transplant recipients.
Audet, P; Dafoe, D; Hedrich, D; Ilson, B; Jorkasky, DK; Shusterman, N; Stote, RM, 1992
)
0.28
" Here we demonstrate that rats will readily self-administer two SKF 38393 analogs, the partial D1 agonist SKF 77434 and the full D1 agonist SKF 82958; both compounds produce inverted U-shaped dose-response curves."( The D1 agonists SKF 82958 and SKF 77434 are self-administered by rats.
Self, DW; Stein, L, 1992
)
0.28
" SCH23390 (3-30 nmol), a selective D1 receptor antagonist, caused a progressive parallel shift to the right of the dose-response curve for YM435-stimulated pancreatic secretion without changing the maximum response."( Effects of YM435, a novel dopamine D1 receptor agonist, on pancreatic exocrine secretion in anesthetized dogs.
Chiba, S; Iwatsuki, K; Ren, LM, 1992
)
0.28
" Dose-response studies between 10(-8) and 10(-4)M concentrations were performed for all drugs."( In vitro responses of equine digital vessels to dopamine and fenoldopam.
Baxter, GM; Moore, JN; Tackett, RL, 1991
)
0.28
" Fenoldopam caused an acute fall in blood pressure which lasted approximately 3 h after dosing and was associated with a reflex tachycardia."( A single dose study of the effects of fenoldopam and enalapril in mild hypertension.
Freestone, S; Jeffrey, RF; Lee, MR; MacDonald, TM, 1991
)
0.28
" Incubation of DA with increasing concentrations of fenoldopam produced parallel rightward shifts in the DA dose-response curves."( Fenoldopam is a partial agonist at dopamine-1 (DA1) receptors in LLC-PK1 cells.
Grenader, A; Healy, DP, 1991
)
0.28
" Fenoldopam and nitroprusside lowered blood pressure safely to an average pressure of 176/105 mm Hg; highly significant dose-response relations were found for the 13 patients receiving fenoldopam and the 15 receiving nitroprusside."( Renal and hemodynamic effects of intravenous fenoldopam versus nitroprusside in severe hypertension.
Elliott, WJ; Fumo, MT; Gretler, DD; McCray, GR; Murphy, MB; Nelson, KS; Oliner, CM; Weber, RR, 1990
)
0.28
" The administration of SKF 30 min before QUIN had no effect on the QUIN dose-response function in either group of rats."( Evaluation of the interaction between D1 and D2 receptors in a drug discrimination paradigm.
Sutherland, JV; Williams, JE; Woolverton, WL, 1990
)
0.28
" Dose-response curves for each drug were shifted to the left in the MPTP-treated mice, suggesting behavioral supersensitivity."( Dopamine receptors and sensorimotor behavior in MPTP-treated mice.
Bruno, JP; Hadjiconstantinou, M; Weihmuller, FB, 1990
)
0.28
"05) shifted the SKF dose-response function to the left, suggesting that stimulation of D2 receptors can potentiate a behavioral effect mediated by D1 receptors."( The D2 agonist quinpirole potentiates the discriminative stimulus effects of the D1 agonist SKF 38393.
Williams, JE; Woolverton, WL, 1990
)
0.28
" The dose-response curves of SKF 38393 were shifted in parallel to the right by butaclamol (3 X 10(-6) and 6 X 10(-6) M) and haloperidol (3 X 10(-6) and 3 X 10(-5) M)."( The relaxing effect of SKF 38393 on the catch contraction of Mytilus smooth muscle.
Ishikawa, T; Murakami, H; Sano, M, 1986
)
0.27
" In mice pretreated with reserpine and various doses of alpha methyl-p-tyrosine (alpha MPT, intraperitoneally), the degree of stimulation produced by (+)-amphetamine was dependent on the amount and frequency of alpha MPT dosage - the higher and more frequent the dose, the more effective the blockade."( The involvement of dopamine D1 and D2 receptors in the locomotor stimulation produced by (+)-amphetamine in naive and dopamine-depleted mice.
Edwards, SR; Jackson, DM; Ross, SB, 1989
)
0.28
" Behaviors measured on day 15 revealed that SKF 38393-treated groups displayed significant deficits, in comparison to controls, in spontaneous alternation and decision-making: less alternation and more vacillatory behavior at every dosage tested."( SKF 38393: vacillatory behavior in immature rats.
Molino, LJ; Shemer, A; Whitaker-Azmitia, PM, 1989
)
0.28
" Pretreatment with sulpiride (200 mg/kg) produced a parallel, 40-fold shift to the right of the dose-response curve for NPA."( Hypothermia in mice: D2 dopamine receptor mediation and absence of spare receptors.
Hizami, R; Kreuter, L; Meller, E, 1989
)
0.28
" In the unblocked group, after PGF2 alpha vasoconstriction, fenoldopam infusion resulted in a dose-dependent decrease in the mean pulmonary arterial pressure with a dose-response curve characteristic for a drug-receptor interaction [Response = -1."( Effect of fenoldopam on preconstricted isolated salt-perfused rat lungs.
Bucciarelli, RL; Drummond, W; Gause, GE; Knight, ME; Polak, MJ, 1989
)
0.28
" A daily levodopa dosage of at least 4 g appears to a prerequisite for long-term response to the drug."( Clinical relevance of long-term therapy with levodopa and orally active dopamine analogues in patients with chronic congestive heart failure.
Hasenfuss, G; Just, H, 1989
)
0.28
" At 24 h post reserpine the dose-response curve of B-HT 920 (0."( Locomotor behaviour of selective dopamine agonists in mice: is endogenous dopamine the only catecholamine involved?
Pichler, L; Pifl, C, 1989
)
0.28
" In addition, the dose-response curve after 5-15 mg/kg bromocriptine administration was parallel to that of apomorphine."( Evidence that the stimulus properties of apomorphine are mediated by both D1 and D2 receptor activation.
Greer, NL; Schechter, MD, 1987
)
0.27
") and shifted to the right the dose-response curve for agonist-induced hypothermia."( SCH 23390 antagonizes apomorphine- and ergot-induced hypothermia.
Carboni, E; Deidda, S; Di Chiara, G; Longoni, R, 1986
)
0.27
" Seven DA agonists produced U-shaped dose-response curves indicative of activity at both the autoreceptor and postsynaptic DA receptor."( Mouse locomotor activity: an in vivo test for dopamine autoreceptor activation.
Bendesky, RJ; Martin, GE, 1984
)
0.27
" A dose-response effect was observed related to alertness, indifference, and locomotion."( Behavioral effects evoked by SKF 38393 and LY 171555 in adult cats.
Gomez, A; Motles, E; Tetas, M, 1995
)
0.29
" Dose-response functions for all four drugs were displaced to the left and average ED50 values were reduced by 3-fold or more under the low-dose compared to the high-dose training condition."( Effects of N-methyl-D-aspartate antagonists in rats discriminating different doses of cocaine: comparison with direct and indirect dopamine agonists.
Edwards, MA; Kantak, KM; Spealman, RD, 1995
)
0.29
" Pretreatment also shifted to the right the dose-response function for DALA intra-accumbens."( Mesoaccumbens dopamine-opiate interactions in the control over behaviour by a conditioned reinforcer.
Everitt, BJ; Phillips, GD; Robbins, TW, 1994
)
0.29
"Methylphenidate (MPD) increased in rats the incidence of sniffing, rearing and locomotion, and this along dose-response curves that had an inverted U-shape; at 40 mg/kg, MPD exclusively induced stereotyped gnawing, which was inhibited by neuroleptics."( Inhibition of methylphenidate-induced behaviors in rats: differences among neuroleptics.
Colpaert, FC; Koek, W, 1993
)
0.29
" In the presence of 200 microM Rp-cAMPS, the dose-response curves of the dopamine D1 receptor agonists SKF 38393 and fenoldopam were shifted to the left and maximal agonist responses were markedly increased."( Inhibition of dopamine agonist-induced phosphoinositide hydrolysis by concomitant stimulation of cyclic AMP formation in brain slices.
Friedman, E; Undie, AS, 1994
)
0.29
" Although carotid arterial pressure did not change significantly after administration of fenoldopam at the dosage of 3 mg/kg, administration of fenoldopam at the dosages of 6 and 9 mg/kg significantly reduced carotid arterial pressure from 113 +/- 10 to 88 +/- 3 and 81 +/- 5 mm of Hg, respectively."( Antagonism of a specific dopaminergic receptor agonist with metoclopramide in horses.
Eades, SC; Moore, JN, 1993
)
0.29
"4 mg/kg and a dose-response relationship similar to that of A68930 (potency ratio 28)."( The dopamine D1 receptor agonists, A68930 and SKF 38393, induce arousal and suppress REM sleep in the rat.
Adami, M; Ferri, N; Ongini, E; Trampus, M, 1993
)
0.29
" SKF 38393 dose-response curves demonstrated enhanced oral activity responses in rats lesioned neonatally with 150 or 200 micrograms of 6-OHDA."( Dose-related effects of a neonatal 6-OHDA lesion on SKF 38393- and m-chlorophenylpiperazine-induced oral activity responses of rats.
Fuller, RW; Gong, L; Kostrzewa, RM; Perry, KW, 1993
)
0.29
" SCH23390 (3-30 nmol), a selective D-1 DA receptor antagonist, caused a progressive parallel shift to the right in the dose-response curve for DA-induced pancreatic secretion without changes in the maximal response."( D-1 dopamine receptors mediate dopamine-induced pancreatic exocrine secretion in anesthetized dogs.
Chiba, S; Horiuchi, A; Iwatsuki, K; Ren, LM, 1995
)
0.29
" Dose-response curves revealed potency differences among drugs in their effects on the two behaviors (e."( Comparison of the effects of prototypical behavioral stimulants on locomotor activity and rotational behavior in rats.
Garrett, BE; Holtzman, SG, 1996
)
0.29
" The results indicate that bicuculline (GABA antagonist), SKF38393 (DA agonist), and ST587 (NE agonist) facilitated retention with little change in the dose-response curves for P8 mice 4, 8, and 12 months of age."( Age-related changes in hippocampal drug facilitation of memory processing in SAMP8 mice.
Flood, JF; Harris, FJ; Morley, JE,
)
0.13
" Following systemic (intraperitoneal) administration of apomorphine (a dopamine receptor D1/D2 mixed agonist), SKF 38393 (D1 > D3 > D2 agonist), LY 17155 or quinpirole (D3 > D2 and D1) agonist), haloperidol (a DA-D2 antagonist), and clonidine (noradrenaline receptor alpha 2 agonist), the ICSS response rates evoked from LH-MFB and VTA-SN were compared with vehicle or saline-treated animals on the basis of dose-response functions."( Dose-response functions of apomorphine, SKF 38393, LY 171555, haloperidol and clonidine on the self-stimulation evoked from lateral hypothalamus and ventral tegmentum.
Desiraju, T; Raju, TR; Singh, J, 1996
)
0.29
" Administration of the D(1) antagonist SCH23390 enhanced the effects of levonantradol, producing a leftward shift of the log dose-response curve."( Cannabinoid and dopamine interaction in rodent brain: effects on locomotor activity.
Conley, TJ; Howlett, AC; Meschler, JP, 2000
)
0.31
" The dissociation constant (K(B)) and relative intrinsic efficacy (E(r)) for each partial agonist were calculated using a partial agonist interaction null model in which the effects of fixed concentrations of each partial agonist on the dopamine dose-response curve were evaluated."( Nonlinear analysis of partial dopamine agonist effects on cAMP in C6 glioma cells.
Abell, C; Avalos, M; Kwan, SW; Mak, C; Randall, PK; Trzeciakowski, JP; Wilcox, RE,
)
0.13
" Both the anorectic response on the first day of dosing and the tolerant response on the subsequent days were attenuated."( Hypothalamic neuropeptide Y (NPY) and the attenuation of hyperphagia in streptozotocin diabetic rats treated with dopamine D1/D2 agonists.
Kuo, DY, 2006
)
0.33
" The nonselective serotonergic antagonist metergoline produced a significant rightward shift of the SKF 38393 dose-response function, indicating effective antagonism, although the degree of antagonism was not dose-related."( Effects of dopamine D1-like receptor agonists on food-maintained operant behavior in rats.
Katz, JL; Kopajtic, TA; Terry, P, 2006
)
0.33
" Although not present in neonate-lesioned rats treated with saline, these morphological changes persisted at least 21 days after repeated dosing with SKF-38393, and were not accompanied by markers of neurodegenerative change."( Changes in apical dendritic structure correlate with sustained ERK1/2 phosphorylation in medial prefrontal cortex of a rat model of dopamine D1 receptor agonist sensitization.
Blake, BL; Breese, GR; Halloran, C; McCown, TJ; Papadeas, ST, 2008
)
0.35
" This study examined the dose-response relationship of the selective D(1) agonist, SKF38393 (0."( D(1) receptor agonists reverse the subchronic phencyclidine (PCP)-induced novel object recognition (NOR) deficit in female rats.
Adelekun, AE; Hannaway, KE; Horiguchi, M; Huang, M; Jayathilake, K; Meltzer, HY, 2013
)
0.39
" Dopamine dose-response curves assaying intracellular calcium mobilization in cells heterologously expressing the D(1) and D(2) subtypes, either alone or in combination, and using subtype selective ligands revealed that concurrent stimulation is required for coupling."( D1-D2 dopamine receptor synergy promotes calcium signaling via multiple mechanisms.
Chun, LS; Doyle, TB; Free, RB; Huang, XP; Rankin, ML; Sibley, DR, 2013
)
0.39
" A second study showed inverted-U shaped dose-response effects of the agonist, such that low levels of sexually motivated song were observed at low and high levels of D1 receptor activation."( Inverted-U shaped effects of D1 dopamine receptor stimulation in the medial preoptic nucleus on sexually motivated song in male European starlings.
Kelm-Nelson, CA; Pawlisch, BA; Riters, LV; Stevenson, SA, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (4)

ClassDescription
benzazepineA group of two-ring heterocyclic compounds consisting of a benzene ring fused to an azepine ring.
catecholsAny compound containing an o-diphenol component.
secondary amino compoundA compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diolA benzazepine that is 2,3,4,5-tetrahydro-3-benzazepine bearing a phenyl substituent at position 1 and two hydroxy substituents at positions 7 and 8.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (58)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency19.95260.177814.390939.8107AID2147
dopamine D1 receptorHomo sapiens (human)Potency0.04610.00521.30228.1995AID624455
thioredoxin reductaseRattus norvegicus (Norway rat)Potency3.57710.100020.879379.4328AID488772; AID588453; AID588456
phosphopantetheinyl transferaseBacillus subtilisPotency79.43280.141337.9142100.0000AID1490
GLS proteinHomo sapiens (human)Potency0.63100.35487.935539.8107AID624146
TDP1 proteinHomo sapiens (human)Potency26.17780.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency16.15950.180013.557439.8107AID1460; AID1468
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
hypothetical protein, conservedTrypanosoma bruceiPotency15.10140.223911.245135.4813AID624147
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency6.70160.035520.977089.1251AID504332
D(1A) dopamine receptorHomo sapiens (human)Potency1.00000.02245.944922.3872AID488983
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID488953
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency3.01310.060110.745337.9330AID485368
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency31.62280.631035.7641100.0000AID504339
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency19.95260.177814.390939.8107AID2147
thioredoxin reductaseRattus norvegicus (Norway rat)Potency15.00300.100020.879379.4328AID588453
GLS proteinHomo sapiens (human)Potency12.58930.35487.935539.8107AID624170
TDP1 proteinHomo sapiens (human)Potency26.10110.000811.382244.6684AID686978; AID686979
hypothetical protein, conservedTrypanosoma bruceiPotency35.48130.223911.245135.4813AID624173
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency35.95700.001530.607315,848.9004AID1224820; AID1224821
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency2.23870.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.31620.540617.639296.1227AID2364; AID2528
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency39.81070.001815.663839.8107AID894
chromobox protein homolog 1Homo sapiens (human)Potency15.84890.006026.168889.1251AID540317
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency8.91250.01789.637444.6684AID588834
M-phase phosphoprotein 8Homo sapiens (human)Potency79.43280.177824.735279.4328AID488949
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)2.80000.00022.45859.9600AID1640021
D(2) dopamine receptorHomo sapiens (human)Ki720.00000.00000.651810.0000AID436902
Alpha-2C adrenergic receptorHomo sapiens (human)Ki0.08320.00030.483410.0000AID1232265
DRattus norvegicus (Norway rat)IC50 (µMol)0.19000.00030.50267.7625AID61015
DRattus norvegicus (Norway rat)Ki0.06410.00010.610010.0000AID61501
D(1A) dopamine receptorHomo sapiens (human)Ki0.32530.00010.836310.0000AID1186139; AID436899; AID436900
D(1B) dopamine receptorHomo sapiens (human)Ki0.12400.00030.40177.9000AID619751
D(2) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)720.00000.00010.54948.4000AID61249
D(2) dopamine receptorRattus norvegicus (Norway rat)Ki6.87000.00000.437510.0000AID65250
D(2) dopamine receptorHomo sapiens (human)Ki4.48000.00000.651810.0000AID61064; AID61066
DRattus norvegicus (Norway rat)IC50 (µMol)34.43000.00030.50267.7625AID62878
D(3) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)34.43000.00030.39075.4000AID62878
D(1A) dopamine receptorHomo sapiens (human)Ki0.01310.00010.836310.0000AID63209
D(1B) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)34.43000.00030.35635.4000AID62878
D(4) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)34.43000.00030.38715.4000AID62878
D(2) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)34.43000.00010.54948.4000AID62878
Cytochrome P450 2C9 Homo sapiens (human)Ki0.07300.00031.684210.0000AID1137629
D(2) dopamine receptorHomo sapiens (human)Ki7.11000.00000.651810.0000AID62918; AID63227
DRattus norvegicus (Norway rat)IC50 (µMol)0.04700.00030.50267.7625AID61015; AID63370
DRattus norvegicus (Norway rat)Ki0.05680.00010.610010.0000AID61494; AID61513; AID61862
Alpha-2B adrenergic receptorRattus norvegicus (Norway rat)Ki3.05000.00000.929610.0000AID37373
D(1A) dopamine receptorHomo sapiens (human)Ki0.12920.00010.836310.0000AID1137629; AID1664376; AID61820; AID63040; AID63344
D(1B) dopamine receptorHomo sapiens (human)Ki0.16430.00030.40177.9000AID1063794; AID1664377
Alpha-2C adrenergic receptorRattus norvegicus (Norway rat)Ki3.05000.00000.970810.0000AID37373
Alpha-2A adrenergic receptorRattus norvegicus (Norway rat)Ki3.05000.00000.937510.0000AID37373
D(2) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)6.87500.00010.54948.4000AID61249; AID64282
D(2) dopamine receptorRattus norvegicus (Norway rat)Ki5.87500.00000.437510.0000AID64301; AID65110; AID65429
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Alpha-2C adrenergic receptorHomo sapiens (human)EC50 (µMol)1.38040.00050.55416.7100AID1232266
D(1A) dopamine receptorHomo sapiens (human)EC50 (µMol)1.44840.00020.47959.5000AID1168797; AID1542816; AID1573447; AID1573449; AID1802076; AID436910; AID673218; AID729710
D(2) dopamine receptorRattus norvegicus (Norway rat)EC50 (µMol)10.00000.00040.32993.9100AID61220
D(2) dopamine receptorRattus norvegicus (Norway rat)Kd56.80000.00030.81836.7000AID64790; AID64917; AID64919; AID64925
Adenylate cyclase type 1 Rattus norvegicus (Norway rat)EC50 (µMol)0.07100.07100.07100.0710AID34440
POsterior SegregationCaenorhabditis elegansEC50 (µMol)108.54602.201047.1808186.6810AID1964
Adenylate cyclase type 3Rattus norvegicus (Norway rat)EC50 (µMol)0.07100.07100.07100.0710AID34440
Sodium-dependent noradrenaline transporter Homo sapiens (human)EC50 (µMol)23.99000.082031.0243168.9080AID1960
Adenylate cyclase type 2Rattus norvegicus (Norway rat)EC50 (µMol)0.07100.07101.03552.0000AID34440
Adenylate cyclase type 4Rattus norvegicus (Norway rat)EC50 (µMol)0.07100.07100.07100.0710AID34440
Adenylate cyclase type 8Rattus norvegicus (Norway rat)EC50 (µMol)0.07100.07100.07100.0710AID34440
Adenylate cyclase type 6Rattus norvegicus (Norway rat)EC50 (µMol)0.07100.07100.07100.0710AID34440
Adenylate cyclase type 5Rattus norvegicus (Norway rat)EC50 (µMol)0.07100.00220.08280.1410AID34440
Adenylyl cyclase 7 Rattus norvegicus (Norway rat)EC50 (µMol)0.07100.07100.07100.0710AID34440
Zinc finger protein mex-5Caenorhabditis elegansEC50 (µMol)23.99000.082033.5679168.9080AID1960
Adenylate cyclase type 6Homo sapiens (human)EC50 (µMol)0.07100.07100.07100.0710AID34592
Adenylate cyclase type 3 Homo sapiens (human)EC50 (µMol)0.07100.07100.07100.0710AID34592
Adenylate cyclase type 9Homo sapiens (human)EC50 (µMol)0.07100.07100.07100.0710AID34592
Adenylate cyclase type 5Homo sapiens (human)EC50 (µMol)0.07550.07100.07550.0800AID34592; AID34598
D(2) dopamine receptorHomo sapiens (human)EC50 (µMol)7.50000.00000.18743.9000AID319299; AID62748
D(2) dopamine receptorHomo sapiens (human)Kd9.50000.00000.64599.5000AID64315
DRattus norvegicus (Norway rat)EC50 (µMol)0.95000.00820.22540.9500AID61858
D(1A) dopamine receptorHomo sapiens (human)EC50 (µMol)0.04450.00020.47959.5000AID319298; AID63211
D(1A) dopamine receptorHomo sapiens (human)Kd0.15000.02801.27634.6000AID61865
D(1) dopamine receptorCarassius auratus (goldfish)EC50 (µMol)0.95000.00820.26750.9500AID61858
Adenylate cyclase type 8Homo sapiens (human)EC50 (µMol)0.07100.07100.08240.0937AID34592
Adenylate cyclase type 7Homo sapiens (human)EC50 (µMol)0.07100.07100.07100.0710AID34592
D(2) dopamine receptorRattus norvegicus (Norway rat)EC50 (µMol)10.00000.00040.32993.9100AID61219
Adenylate cyclase type 2Homo sapiens (human)EC50 (µMol)0.07100.07100.07100.0710AID34592
Adenylate cyclase type 1Homo sapiens (human)EC50 (µMol)0.07100.07100.28550.5000AID34592
Adenylate cyclase type 4Homo sapiens (human)EC50 (µMol)0.07100.07100.07100.0710AID34592
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
jumonji domain containing 2C, partialHomo sapiens (human)AC5015.21000.42456.746215.2100AID488835
FAD-linked sulfhydryl oxidase ALRHomo sapiens (human)AC505.38000.00503.212622.7870AID493248
Adenylate cyclase type 5Homo sapiens (human)ED500.06300.06300.06300.0630AID34601
DRattus norvegicus (Norway rat)K0.50.01700.00030.01430.1490AID61347
DRattus norvegicus (Norway rat)KL0.38100.02100.44030.7340AID61996
D(2) dopamine receptorBos taurus (cattle)K bind33.90000.21000.21000.2100AID62184
Histamine H2 receptorCavia porcellus (domestic guinea pig)K0.52.50000.00010.40364.8000AID88009
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (224)

Processvia Protein(s)Taxonomy
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
temperature homeostasisD(2) dopamine receptorHomo sapiens (human)
response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein phosphorylationD(2) dopamine receptorHomo sapiens (human)
response to amphetamineD(2) dopamine receptorHomo sapiens (human)
nervous system process involved in regulation of systemic arterial blood pressureD(2) dopamine receptorHomo sapiens (human)
regulation of heart rateD(2) dopamine receptorHomo sapiens (human)
regulation of sodium ion transportD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(2) dopamine receptorHomo sapiens (human)
positive regulation of neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
positive regulation of receptor internalizationD(2) dopamine receptorHomo sapiens (human)
autophagyD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
neuron-neuron synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
axonogenesisD(2) dopamine receptorHomo sapiens (human)
synapse assemblyD(2) dopamine receptorHomo sapiens (human)
sensory perception of smellD(2) dopamine receptorHomo sapiens (human)
long-term memoryD(2) dopamine receptorHomo sapiens (human)
grooming behaviorD(2) dopamine receptorHomo sapiens (human)
locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
adult walking behaviorD(2) dopamine receptorHomo sapiens (human)
protein localizationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell population proliferationD(2) dopamine receptorHomo sapiens (human)
associative learningD(2) dopamine receptorHomo sapiens (human)
visual learningD(2) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(2) dopamine receptorHomo sapiens (human)
response to light stimulusD(2) dopamine receptorHomo sapiens (human)
response to toxic substanceD(2) dopamine receptorHomo sapiens (human)
response to iron ionD(2) dopamine receptorHomo sapiens (human)
response to inactivityD(2) dopamine receptorHomo sapiens (human)
Wnt signaling pathwayD(2) dopamine receptorHomo sapiens (human)
striatum developmentD(2) dopamine receptorHomo sapiens (human)
orbitofrontal cortex developmentD(2) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(2) dopamine receptorHomo sapiens (human)
adenohypophysis developmentD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell migrationD(2) dopamine receptorHomo sapiens (human)
peristalsisD(2) dopamine receptorHomo sapiens (human)
auditory behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of synaptic transmission, GABAergicD(2) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(2) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
response to histamineD(2) dopamine receptorHomo sapiens (human)
response to nicotineD(2) dopamine receptorHomo sapiens (human)
positive regulation of urine volumeD(2) dopamine receptorHomo sapiens (human)
positive regulation of renal sodium excretionD(2) dopamine receptorHomo sapiens (human)
positive regulation of multicellular organism growthD(2) dopamine receptorHomo sapiens (human)
response to cocaineD(2) dopamine receptorHomo sapiens (human)
negative regulation of circadian sleep/wake cycle, sleepD(2) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(2) dopamine receptorHomo sapiens (human)
drinking behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(2) dopamine receptorHomo sapiens (human)
response to morphineD(2) dopamine receptorHomo sapiens (human)
pigmentationD(2) dopamine receptorHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
positive regulation of G protein-coupled receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(2) dopamine receptorHomo sapiens (human)
negative regulation of innate immune responseD(2) dopamine receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IID(2) dopamine receptorHomo sapiens (human)
negative regulation of insulin secretionD(2) dopamine receptorHomo sapiens (human)
acid secretionD(2) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(2) dopamine receptorHomo sapiens (human)
behavioral response to ethanolD(2) dopamine receptorHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityD(2) dopamine receptorHomo sapiens (human)
response to axon injuryD(2) dopamine receptorHomo sapiens (human)
branching morphogenesis of a nerveD(2) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(2) dopamine receptorHomo sapiens (human)
epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(2) dopamine receptorHomo sapiens (human)
release of sequestered calcium ion into cytosolD(2) dopamine receptorHomo sapiens (human)
dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of synapse structural plasticityD(2) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(2) dopamine receptorHomo sapiens (human)
excitatory postsynaptic potentialD(2) dopamine receptorHomo sapiens (human)
positive regulation of growth hormone secretionD(2) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeD(2) dopamine receptorHomo sapiens (human)
regulation of locomotion involved in locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
negative regulation of cellular response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
positive regulation of glial cell-derived neurotrophic factor productionD(2) dopamine receptorHomo sapiens (human)
positive regulation of long-term synaptic potentiationD(2) dopamine receptorHomo sapiens (human)
hyaloid vascular plexus regressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of neuron migrationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(2) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(2) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
regulation of smooth muscle contractionAlpha-2C adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2C adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2C adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2C adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2C adrenergic receptorHomo sapiens (human)
temperature homeostasisD(1A) dopamine receptorHomo sapiens (human)
conditioned taste aversionD(1A) dopamine receptorHomo sapiens (human)
behavioral fear responseD(1A) dopamine receptorHomo sapiens (human)
regulation of protein phosphorylationD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(1A) dopamine receptorHomo sapiens (human)
response to amphetamineD(1A) dopamine receptorHomo sapiens (human)
protein import into nucleusD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
activation of adenylate cyclase activityD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
synapse assemblyD(1A) dopamine receptorHomo sapiens (human)
memoryD(1A) dopamine receptorHomo sapiens (human)
mating behaviorD(1A) dopamine receptorHomo sapiens (human)
grooming behaviorD(1A) dopamine receptorHomo sapiens (human)
adult walking behaviorD(1A) dopamine receptorHomo sapiens (human)
visual learningD(1A) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(1A) dopamine receptorHomo sapiens (human)
astrocyte developmentD(1A) dopamine receptorHomo sapiens (human)
dopamine transportD(1A) dopamine receptorHomo sapiens (human)
transmission of nerve impulseD(1A) dopamine receptorHomo sapiens (human)
neuronal action potentialD(1A) dopamine receptorHomo sapiens (human)
dentate gyrus developmentD(1A) dopamine receptorHomo sapiens (human)
striatum developmentD(1A) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of cell migrationD(1A) dopamine receptorHomo sapiens (human)
peristalsisD(1A) dopamine receptorHomo sapiens (human)
operant conditioningD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
vasodilationD(1A) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
maternal behaviorD(1A) dopamine receptorHomo sapiens (human)
positive regulation of potassium ion transportD(1A) dopamine receptorHomo sapiens (human)
glucose importD(1A) dopamine receptorHomo sapiens (human)
habituationD(1A) dopamine receptorHomo sapiens (human)
sensitizationD(1A) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(1A) dopamine receptorHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(1A) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic potentiationD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic depressionD(1A) dopamine receptorHomo sapiens (human)
cellular response to catecholamine stimulusD(1A) dopamine receptorHomo sapiens (human)
modification of postsynaptic structureD(1A) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of neuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(1B) dopamine receptorHomo sapiens (human)
response to amphetamineD(1B) dopamine receptorHomo sapiens (human)
regulation of systemic arterial blood pressure by vasopressinD(1B) dopamine receptorHomo sapiens (human)
norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressureD(1B) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(1B) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayD(1B) dopamine receptorHomo sapiens (human)
activation of adenylate cyclase activityD(1B) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(1B) dopamine receptorHomo sapiens (human)
chemical synaptic transmissionD(1B) dopamine receptorHomo sapiens (human)
associative learningD(1B) dopamine receptorHomo sapiens (human)
transmission of nerve impulseD(1B) dopamine receptorHomo sapiens (human)
negative regulation of NAD(P)H oxidase activityD(1B) dopamine receptorHomo sapiens (human)
wound healingD(1B) dopamine receptorHomo sapiens (human)
response to cocaineD(1B) dopamine receptorHomo sapiens (human)
positive regulation of adenylate cyclase activityD(1B) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(1B) dopamine receptorHomo sapiens (human)
regulation of female receptivityD(1B) dopamine receptorHomo sapiens (human)
sensitizationD(1B) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(1B) dopamine receptorHomo sapiens (human)
long-term synaptic depressionD(1B) dopamine receptorHomo sapiens (human)
cellular response to catecholamine stimulusD(1B) dopamine receptorHomo sapiens (human)
reactive oxygen species metabolic processD(1B) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(1B) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(1B) dopamine receptorHomo sapiens (human)
dopamine receptor signaling pathwayD(1B) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
temperature homeostasisD(2) dopamine receptorHomo sapiens (human)
response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein phosphorylationD(2) dopamine receptorHomo sapiens (human)
response to amphetamineD(2) dopamine receptorHomo sapiens (human)
nervous system process involved in regulation of systemic arterial blood pressureD(2) dopamine receptorHomo sapiens (human)
regulation of heart rateD(2) dopamine receptorHomo sapiens (human)
regulation of sodium ion transportD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(2) dopamine receptorHomo sapiens (human)
positive regulation of neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
positive regulation of receptor internalizationD(2) dopamine receptorHomo sapiens (human)
autophagyD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
neuron-neuron synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
axonogenesisD(2) dopamine receptorHomo sapiens (human)
synapse assemblyD(2) dopamine receptorHomo sapiens (human)
sensory perception of smellD(2) dopamine receptorHomo sapiens (human)
long-term memoryD(2) dopamine receptorHomo sapiens (human)
grooming behaviorD(2) dopamine receptorHomo sapiens (human)
locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
adult walking behaviorD(2) dopamine receptorHomo sapiens (human)
protein localizationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell population proliferationD(2) dopamine receptorHomo sapiens (human)
associative learningD(2) dopamine receptorHomo sapiens (human)
visual learningD(2) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(2) dopamine receptorHomo sapiens (human)
response to light stimulusD(2) dopamine receptorHomo sapiens (human)
response to toxic substanceD(2) dopamine receptorHomo sapiens (human)
response to iron ionD(2) dopamine receptorHomo sapiens (human)
response to inactivityD(2) dopamine receptorHomo sapiens (human)
Wnt signaling pathwayD(2) dopamine receptorHomo sapiens (human)
striatum developmentD(2) dopamine receptorHomo sapiens (human)
orbitofrontal cortex developmentD(2) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(2) dopamine receptorHomo sapiens (human)
adenohypophysis developmentD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell migrationD(2) dopamine receptorHomo sapiens (human)
peristalsisD(2) dopamine receptorHomo sapiens (human)
auditory behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of synaptic transmission, GABAergicD(2) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(2) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
response to histamineD(2) dopamine receptorHomo sapiens (human)
response to nicotineD(2) dopamine receptorHomo sapiens (human)
positive regulation of urine volumeD(2) dopamine receptorHomo sapiens (human)
positive regulation of renal sodium excretionD(2) dopamine receptorHomo sapiens (human)
positive regulation of multicellular organism growthD(2) dopamine receptorHomo sapiens (human)
response to cocaineD(2) dopamine receptorHomo sapiens (human)
negative regulation of circadian sleep/wake cycle, sleepD(2) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(2) dopamine receptorHomo sapiens (human)
drinking behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(2) dopamine receptorHomo sapiens (human)
response to morphineD(2) dopamine receptorHomo sapiens (human)
pigmentationD(2) dopamine receptorHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
positive regulation of G protein-coupled receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(2) dopamine receptorHomo sapiens (human)
negative regulation of innate immune responseD(2) dopamine receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IID(2) dopamine receptorHomo sapiens (human)
negative regulation of insulin secretionD(2) dopamine receptorHomo sapiens (human)
acid secretionD(2) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(2) dopamine receptorHomo sapiens (human)
behavioral response to ethanolD(2) dopamine receptorHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityD(2) dopamine receptorHomo sapiens (human)
response to axon injuryD(2) dopamine receptorHomo sapiens (human)
branching morphogenesis of a nerveD(2) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(2) dopamine receptorHomo sapiens (human)
epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(2) dopamine receptorHomo sapiens (human)
release of sequestered calcium ion into cytosolD(2) dopamine receptorHomo sapiens (human)
dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of synapse structural plasticityD(2) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(2) dopamine receptorHomo sapiens (human)
excitatory postsynaptic potentialD(2) dopamine receptorHomo sapiens (human)
positive regulation of growth hormone secretionD(2) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeD(2) dopamine receptorHomo sapiens (human)
regulation of locomotion involved in locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
negative regulation of cellular response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
positive regulation of glial cell-derived neurotrophic factor productionD(2) dopamine receptorHomo sapiens (human)
positive regulation of long-term synaptic potentiationD(2) dopamine receptorHomo sapiens (human)
hyaloid vascular plexus regressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of neuron migrationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(2) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(2) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
temperature homeostasisD(1A) dopamine receptorHomo sapiens (human)
conditioned taste aversionD(1A) dopamine receptorHomo sapiens (human)
behavioral fear responseD(1A) dopamine receptorHomo sapiens (human)
regulation of protein phosphorylationD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(1A) dopamine receptorHomo sapiens (human)
response to amphetamineD(1A) dopamine receptorHomo sapiens (human)
protein import into nucleusD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
activation of adenylate cyclase activityD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
synapse assemblyD(1A) dopamine receptorHomo sapiens (human)
memoryD(1A) dopamine receptorHomo sapiens (human)
mating behaviorD(1A) dopamine receptorHomo sapiens (human)
grooming behaviorD(1A) dopamine receptorHomo sapiens (human)
adult walking behaviorD(1A) dopamine receptorHomo sapiens (human)
visual learningD(1A) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(1A) dopamine receptorHomo sapiens (human)
astrocyte developmentD(1A) dopamine receptorHomo sapiens (human)
dopamine transportD(1A) dopamine receptorHomo sapiens (human)
transmission of nerve impulseD(1A) dopamine receptorHomo sapiens (human)
neuronal action potentialD(1A) dopamine receptorHomo sapiens (human)
dentate gyrus developmentD(1A) dopamine receptorHomo sapiens (human)
striatum developmentD(1A) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of cell migrationD(1A) dopamine receptorHomo sapiens (human)
peristalsisD(1A) dopamine receptorHomo sapiens (human)
operant conditioningD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
vasodilationD(1A) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
maternal behaviorD(1A) dopamine receptorHomo sapiens (human)
positive regulation of potassium ion transportD(1A) dopamine receptorHomo sapiens (human)
glucose importD(1A) dopamine receptorHomo sapiens (human)
habituationD(1A) dopamine receptorHomo sapiens (human)
sensitizationD(1A) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(1A) dopamine receptorHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(1A) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic potentiationD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic depressionD(1A) dopamine receptorHomo sapiens (human)
cellular response to catecholamine stimulusD(1A) dopamine receptorHomo sapiens (human)
modification of postsynaptic structureD(1A) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of neuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
monoamine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent noradrenaline transporter Homo sapiens (human)
chemical synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent noradrenaline transporter Homo sapiens (human)
response to painSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent noradrenaline transporter Homo sapiens (human)
neuron cellular homeostasisSodium-dependent noradrenaline transporter Homo sapiens (human)
amino acid transportSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent noradrenaline transporter Homo sapiens (human)
renal water homeostasisAdenylate cyclase type 6Homo sapiens (human)
cAMP biosynthetic processAdenylate cyclase type 6Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenylate cyclase type 6Homo sapiens (human)
dopamine receptor signaling pathwayAdenylate cyclase type 6Homo sapiens (human)
negative regulation of neuron projection developmentAdenylate cyclase type 6Homo sapiens (human)
intracellular signal transductionAdenylate cyclase type 6Homo sapiens (human)
negative regulation of urine volumeAdenylate cyclase type 6Homo sapiens (human)
cellular response to prostaglandin E stimulusAdenylate cyclase type 6Homo sapiens (human)
cellular response to catecholamine stimulusAdenylate cyclase type 6Homo sapiens (human)
blood vessel diameter maintenanceAdenylate cyclase type 6Homo sapiens (human)
cellular response to vasopressinAdenylate cyclase type 6Homo sapiens (human)
cellular response to forskolinAdenylate cyclase type 6Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAdenylate cyclase type 6Homo sapiens (human)
cAMP biosynthetic processAdenylate cyclase type 3 Homo sapiens (human)
signal transductionAdenylate cyclase type 3 Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenylate cyclase type 3 Homo sapiens (human)
single fertilizationAdenylate cyclase type 3 Homo sapiens (human)
acrosome reactionAdenylate cyclase type 3 Homo sapiens (human)
sensory perception of smellAdenylate cyclase type 3 Homo sapiens (human)
olfactory learningAdenylate cyclase type 3 Homo sapiens (human)
flagellated sperm motilityAdenylate cyclase type 3 Homo sapiens (human)
intracellular signal transductionAdenylate cyclase type 3 Homo sapiens (human)
cellular response to forskolinAdenylate cyclase type 3 Homo sapiens (human)
in utero embryonic developmentAdenylate cyclase type 9Homo sapiens (human)
cAMP biosynthetic processAdenylate cyclase type 9Homo sapiens (human)
signal transductionAdenylate cyclase type 9Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenylate cyclase type 9Homo sapiens (human)
intracellular signal transductionAdenylate cyclase type 9Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAdenylate cyclase type 9Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenylate cyclase type 5Homo sapiens (human)
cAMP biosynthetic processAdenylate cyclase type 5Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenylate cyclase type 5Homo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayAdenylate cyclase type 5Homo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayAdenylate cyclase type 5Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAdenylate cyclase type 5Homo sapiens (human)
locomotory behaviorAdenylate cyclase type 5Homo sapiens (human)
intracellular signal transductionAdenylate cyclase type 5Homo sapiens (human)
neuromuscular process controlling balanceAdenylate cyclase type 5Homo sapiens (human)
regulation of insulin secretion involved in cellular response to glucose stimulusAdenylate cyclase type 5Homo sapiens (human)
cellular response to forskolinAdenylate cyclase type 5Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAdenylate cyclase type 5Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
temperature homeostasisD(2) dopamine receptorHomo sapiens (human)
response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein phosphorylationD(2) dopamine receptorHomo sapiens (human)
response to amphetamineD(2) dopamine receptorHomo sapiens (human)
nervous system process involved in regulation of systemic arterial blood pressureD(2) dopamine receptorHomo sapiens (human)
regulation of heart rateD(2) dopamine receptorHomo sapiens (human)
regulation of sodium ion transportD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(2) dopamine receptorHomo sapiens (human)
positive regulation of neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
positive regulation of receptor internalizationD(2) dopamine receptorHomo sapiens (human)
autophagyD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
neuron-neuron synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
axonogenesisD(2) dopamine receptorHomo sapiens (human)
synapse assemblyD(2) dopamine receptorHomo sapiens (human)
sensory perception of smellD(2) dopamine receptorHomo sapiens (human)
long-term memoryD(2) dopamine receptorHomo sapiens (human)
grooming behaviorD(2) dopamine receptorHomo sapiens (human)
locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
adult walking behaviorD(2) dopamine receptorHomo sapiens (human)
protein localizationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell population proliferationD(2) dopamine receptorHomo sapiens (human)
associative learningD(2) dopamine receptorHomo sapiens (human)
visual learningD(2) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(2) dopamine receptorHomo sapiens (human)
response to light stimulusD(2) dopamine receptorHomo sapiens (human)
response to toxic substanceD(2) dopamine receptorHomo sapiens (human)
response to iron ionD(2) dopamine receptorHomo sapiens (human)
response to inactivityD(2) dopamine receptorHomo sapiens (human)
Wnt signaling pathwayD(2) dopamine receptorHomo sapiens (human)
striatum developmentD(2) dopamine receptorHomo sapiens (human)
orbitofrontal cortex developmentD(2) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(2) dopamine receptorHomo sapiens (human)
adenohypophysis developmentD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell migrationD(2) dopamine receptorHomo sapiens (human)
peristalsisD(2) dopamine receptorHomo sapiens (human)
auditory behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of synaptic transmission, GABAergicD(2) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(2) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
response to histamineD(2) dopamine receptorHomo sapiens (human)
response to nicotineD(2) dopamine receptorHomo sapiens (human)
positive regulation of urine volumeD(2) dopamine receptorHomo sapiens (human)
positive regulation of renal sodium excretionD(2) dopamine receptorHomo sapiens (human)
positive regulation of multicellular organism growthD(2) dopamine receptorHomo sapiens (human)
response to cocaineD(2) dopamine receptorHomo sapiens (human)
negative regulation of circadian sleep/wake cycle, sleepD(2) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(2) dopamine receptorHomo sapiens (human)
drinking behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(2) dopamine receptorHomo sapiens (human)
response to morphineD(2) dopamine receptorHomo sapiens (human)
pigmentationD(2) dopamine receptorHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
positive regulation of G protein-coupled receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(2) dopamine receptorHomo sapiens (human)
negative regulation of innate immune responseD(2) dopamine receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IID(2) dopamine receptorHomo sapiens (human)
negative regulation of insulin secretionD(2) dopamine receptorHomo sapiens (human)
acid secretionD(2) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(2) dopamine receptorHomo sapiens (human)
behavioral response to ethanolD(2) dopamine receptorHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityD(2) dopamine receptorHomo sapiens (human)
response to axon injuryD(2) dopamine receptorHomo sapiens (human)
branching morphogenesis of a nerveD(2) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(2) dopamine receptorHomo sapiens (human)
epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(2) dopamine receptorHomo sapiens (human)
release of sequestered calcium ion into cytosolD(2) dopamine receptorHomo sapiens (human)
dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of synapse structural plasticityD(2) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(2) dopamine receptorHomo sapiens (human)
excitatory postsynaptic potentialD(2) dopamine receptorHomo sapiens (human)
positive regulation of growth hormone secretionD(2) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeD(2) dopamine receptorHomo sapiens (human)
regulation of locomotion involved in locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
negative regulation of cellular response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
positive regulation of glial cell-derived neurotrophic factor productionD(2) dopamine receptorHomo sapiens (human)
positive regulation of long-term synaptic potentiationD(2) dopamine receptorHomo sapiens (human)
hyaloid vascular plexus regressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of neuron migrationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(2) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(2) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(2) dopamine receptorBos taurus (cattle)
negative regulation of prolactin secretionD(2) dopamine receptorBos taurus (cattle)
negative regulation of lactationD(2) dopamine receptorBos taurus (cattle)
positive regulation of mammary gland involutionD(2) dopamine receptorBos taurus (cattle)
hyaloid vascular plexus regressionD(2) dopamine receptorBos taurus (cattle)
temperature homeostasisD(1A) dopamine receptorHomo sapiens (human)
conditioned taste aversionD(1A) dopamine receptorHomo sapiens (human)
behavioral fear responseD(1A) dopamine receptorHomo sapiens (human)
regulation of protein phosphorylationD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(1A) dopamine receptorHomo sapiens (human)
response to amphetamineD(1A) dopamine receptorHomo sapiens (human)
protein import into nucleusD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
activation of adenylate cyclase activityD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
synapse assemblyD(1A) dopamine receptorHomo sapiens (human)
memoryD(1A) dopamine receptorHomo sapiens (human)
mating behaviorD(1A) dopamine receptorHomo sapiens (human)
grooming behaviorD(1A) dopamine receptorHomo sapiens (human)
adult walking behaviorD(1A) dopamine receptorHomo sapiens (human)
visual learningD(1A) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(1A) dopamine receptorHomo sapiens (human)
astrocyte developmentD(1A) dopamine receptorHomo sapiens (human)
dopamine transportD(1A) dopamine receptorHomo sapiens (human)
transmission of nerve impulseD(1A) dopamine receptorHomo sapiens (human)
neuronal action potentialD(1A) dopamine receptorHomo sapiens (human)
dentate gyrus developmentD(1A) dopamine receptorHomo sapiens (human)
striatum developmentD(1A) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of cell migrationD(1A) dopamine receptorHomo sapiens (human)
peristalsisD(1A) dopamine receptorHomo sapiens (human)
operant conditioningD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
vasodilationD(1A) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
maternal behaviorD(1A) dopamine receptorHomo sapiens (human)
positive regulation of potassium ion transportD(1A) dopamine receptorHomo sapiens (human)
glucose importD(1A) dopamine receptorHomo sapiens (human)
habituationD(1A) dopamine receptorHomo sapiens (human)
sensitizationD(1A) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(1A) dopamine receptorHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(1A) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic potentiationD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic depressionD(1A) dopamine receptorHomo sapiens (human)
cellular response to catecholamine stimulusD(1A) dopamine receptorHomo sapiens (human)
modification of postsynaptic structureD(1A) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of neuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(1B) dopamine receptorHomo sapiens (human)
response to amphetamineD(1B) dopamine receptorHomo sapiens (human)
regulation of systemic arterial blood pressure by vasopressinD(1B) dopamine receptorHomo sapiens (human)
norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressureD(1B) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(1B) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayD(1B) dopamine receptorHomo sapiens (human)
activation of adenylate cyclase activityD(1B) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(1B) dopamine receptorHomo sapiens (human)
chemical synaptic transmissionD(1B) dopamine receptorHomo sapiens (human)
associative learningD(1B) dopamine receptorHomo sapiens (human)
transmission of nerve impulseD(1B) dopamine receptorHomo sapiens (human)
negative regulation of NAD(P)H oxidase activityD(1B) dopamine receptorHomo sapiens (human)
wound healingD(1B) dopamine receptorHomo sapiens (human)
response to cocaineD(1B) dopamine receptorHomo sapiens (human)
positive regulation of adenylate cyclase activityD(1B) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(1B) dopamine receptorHomo sapiens (human)
regulation of female receptivityD(1B) dopamine receptorHomo sapiens (human)
sensitizationD(1B) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(1B) dopamine receptorHomo sapiens (human)
long-term synaptic depressionD(1B) dopamine receptorHomo sapiens (human)
cellular response to catecholamine stimulusD(1B) dopamine receptorHomo sapiens (human)
reactive oxygen species metabolic processD(1B) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(1B) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(1B) dopamine receptorHomo sapiens (human)
dopamine receptor signaling pathwayD(1B) dopamine receptorHomo sapiens (human)
signal transductionAdenylate cyclase type 8Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAdenylate cyclase type 8Homo sapiens (human)
learning or memoryAdenylate cyclase type 8Homo sapiens (human)
memoryAdenylate cyclase type 8Homo sapiens (human)
long-term memoryAdenylate cyclase type 8Homo sapiens (human)
locomotory behaviorAdenylate cyclase type 8Homo sapiens (human)
glucose mediated signaling pathwayAdenylate cyclase type 8Homo sapiens (human)
positive regulation of synaptic plasticityAdenylate cyclase type 8Homo sapiens (human)
positive regulation of CREB transcription factor activityAdenylate cyclase type 8Homo sapiens (human)
activation of protein kinase A activityAdenylate cyclase type 8Homo sapiens (human)
intracellular signal transductionAdenylate cyclase type 8Homo sapiens (human)
positive regulation of insulin secretion involved in cellular response to glucose stimulusAdenylate cyclase type 8Homo sapiens (human)
G protein-coupled opioid receptor signaling pathwayAdenylate cyclase type 8Homo sapiens (human)
glucose homeostasisAdenylate cyclase type 8Homo sapiens (human)
regulation of insulin secretionAdenylate cyclase type 8Homo sapiens (human)
protein complex oligomerizationAdenylate cyclase type 8Homo sapiens (human)
protein homooligomerizationAdenylate cyclase type 8Homo sapiens (human)
regulation of cytosolic calcium ion concentrationAdenylate cyclase type 8Homo sapiens (human)
cellular response to calcium ionAdenylate cyclase type 8Homo sapiens (human)
cellular response to morphineAdenylate cyclase type 8Homo sapiens (human)
cellular response to glucose stimulusAdenylate cyclase type 8Homo sapiens (human)
cellular response to glucagon stimulusAdenylate cyclase type 8Homo sapiens (human)
regulation of cellular response to stressAdenylate cyclase type 8Homo sapiens (human)
neuroinflammatory responseAdenylate cyclase type 8Homo sapiens (human)
positive regulation of long-term synaptic potentiationAdenylate cyclase type 8Homo sapiens (human)
positive regulation of long-term synaptic depressionAdenylate cyclase type 8Homo sapiens (human)
cellular response to forskolinAdenylate cyclase type 8Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenylate cyclase type 8Homo sapiens (human)
cAMP biosynthetic processAdenylate cyclase type 8Homo sapiens (human)
regulation of adaptive immune responseAdenylate cyclase type 7Homo sapiens (human)
cAMP biosynthetic processAdenylate cyclase type 7Homo sapiens (human)
intracellular signal transductionAdenylate cyclase type 7Homo sapiens (human)
maternal process involved in female pregnancyAdenylate cyclase type 7Homo sapiens (human)
cellular response to lithium ionAdenylate cyclase type 7Homo sapiens (human)
cellular response to ethanolAdenylate cyclase type 7Homo sapiens (human)
negative regulation of cytokine production involved in inflammatory responseAdenylate cyclase type 7Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenylate cyclase type 7Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAdenylate cyclase type 7Homo sapiens (human)
cAMP biosynthetic processAdenylate cyclase type 2Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAdenylate cyclase type 2Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenylate cyclase type 2Homo sapiens (human)
cAMP-mediated signalingAdenylate cyclase type 2Homo sapiens (human)
cellular response to forskolinAdenylate cyclase type 2Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAdenylate cyclase type 2Homo sapiens (human)
cAMP biosynthetic processAdenylate cyclase type 1Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenylate cyclase type 1Homo sapiens (human)
axonogenesisAdenylate cyclase type 1Homo sapiens (human)
long-term memoryAdenylate cyclase type 1Homo sapiens (human)
circadian rhythmAdenylate cyclase type 1Homo sapiens (human)
response to xenobiotic stimulusAdenylate cyclase type 1Homo sapiens (human)
cAMP-mediated signalingAdenylate cyclase type 1Homo sapiens (human)
positive regulation of CREB transcription factor activityAdenylate cyclase type 1Homo sapiens (human)
regulation of circadian rhythmAdenylate cyclase type 1Homo sapiens (human)
cellular response to calcium ionAdenylate cyclase type 1Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenylate cyclase type 1Homo sapiens (human)
neuroinflammatory responseAdenylate cyclase type 1Homo sapiens (human)
positive regulation of long-term synaptic potentiationAdenylate cyclase type 1Homo sapiens (human)
cellular response to forskolinAdenylate cyclase type 1Homo sapiens (human)
cAMP biosynthetic processAdenylate cyclase type 4Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAdenylate cyclase type 4Homo sapiens (human)
intracellular signal transductionAdenylate cyclase type 4Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAdenylate cyclase type 4Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenylate cyclase type 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (63)

Processvia Protein(s)Taxonomy
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(2) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(2) dopamine receptorHomo sapiens (human)
protein bindingD(2) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(2) dopamine receptorHomo sapiens (human)
dopamine bindingD(2) dopamine receptorHomo sapiens (human)
ionotropic glutamate receptor bindingD(2) dopamine receptorHomo sapiens (human)
identical protein bindingD(2) dopamine receptorHomo sapiens (human)
heterocyclic compound bindingD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(2) dopamine receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2C adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingAlpha-2C adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2C adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2C adrenergic receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via GsD(1A) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activityD(1A) dopamine receptorHomo sapiens (human)
protein bindingD(1A) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine bindingD(1A) dopamine receptorHomo sapiens (human)
arrestin family protein bindingD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(1A) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via GsD(1B) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activityD(1B) dopamine receptorHomo sapiens (human)
protein bindingD(1B) dopamine receptorHomo sapiens (human)
dopamine bindingD(1B) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(1B) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(2) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(2) dopamine receptorHomo sapiens (human)
protein bindingD(2) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(2) dopamine receptorHomo sapiens (human)
dopamine bindingD(2) dopamine receptorHomo sapiens (human)
ionotropic glutamate receptor bindingD(2) dopamine receptorHomo sapiens (human)
identical protein bindingD(2) dopamine receptorHomo sapiens (human)
heterocyclic compound bindingD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(2) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via GsD(1A) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activityD(1A) dopamine receptorHomo sapiens (human)
protein bindingD(1A) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine bindingD(1A) dopamine receptorHomo sapiens (human)
arrestin family protein bindingD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase activityAdenylate cyclase type 3Rattus norvegicus (Norway rat)
actin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
protein bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
alpha-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
metal ion bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
beta-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
adenylate cyclase activityAdenylate cyclase type 6Homo sapiens (human)
protein kinase C bindingAdenylate cyclase type 6Homo sapiens (human)
protein bindingAdenylate cyclase type 6Homo sapiens (human)
ATP bindingAdenylate cyclase type 6Homo sapiens (human)
protein kinase bindingAdenylate cyclase type 6Homo sapiens (human)
metal ion bindingAdenylate cyclase type 6Homo sapiens (human)
adenylate cyclase activityAdenylate cyclase type 3 Homo sapiens (human)
calmodulin bindingAdenylate cyclase type 3 Homo sapiens (human)
ATP bindingAdenylate cyclase type 3 Homo sapiens (human)
metal ion bindingAdenylate cyclase type 3 Homo sapiens (human)
adenylate cyclase activityAdenylate cyclase type 9Homo sapiens (human)
ATP bindingAdenylate cyclase type 9Homo sapiens (human)
metal ion bindingAdenylate cyclase type 9Homo sapiens (human)
adenylate cyclase activityAdenylate cyclase type 5Homo sapiens (human)
ATP bindingAdenylate cyclase type 5Homo sapiens (human)
adenylate cyclase bindingAdenylate cyclase type 5Homo sapiens (human)
metal ion bindingAdenylate cyclase type 5Homo sapiens (human)
scaffold protein bindingAdenylate cyclase type 5Homo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(2) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(2) dopamine receptorHomo sapiens (human)
protein bindingD(2) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(2) dopamine receptorHomo sapiens (human)
dopamine bindingD(2) dopamine receptorHomo sapiens (human)
ionotropic glutamate receptor bindingD(2) dopamine receptorHomo sapiens (human)
identical protein bindingD(2) dopamine receptorHomo sapiens (human)
heterocyclic compound bindingD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(2) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via GsD(1A) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activityD(1A) dopamine receptorHomo sapiens (human)
protein bindingD(1A) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine bindingD(1A) dopamine receptorHomo sapiens (human)
arrestin family protein bindingD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(1A) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via GsD(1B) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activityD(1B) dopamine receptorHomo sapiens (human)
protein bindingD(1B) dopamine receptorHomo sapiens (human)
dopamine bindingD(1B) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(1B) dopamine receptorHomo sapiens (human)
actin bindingAdenylate cyclase type 8Homo sapiens (human)
adenylate cyclase activityAdenylate cyclase type 8Homo sapiens (human)
calmodulin bindingAdenylate cyclase type 8Homo sapiens (human)
ATP bindingAdenylate cyclase type 8Homo sapiens (human)
calcium- and calmodulin-responsive adenylate cyclase activityAdenylate cyclase type 8Homo sapiens (human)
protein homodimerization activityAdenylate cyclase type 8Homo sapiens (human)
metal ion bindingAdenylate cyclase type 8Homo sapiens (human)
protein heterodimerization activityAdenylate cyclase type 8Homo sapiens (human)
protein dimerization activityAdenylate cyclase type 8Homo sapiens (human)
protein phosphatase 2A bindingAdenylate cyclase type 8Homo sapiens (human)
adenylate cyclase activityAdenylate cyclase type 7Homo sapiens (human)
ATP bindingAdenylate cyclase type 7Homo sapiens (human)
metal ion bindingAdenylate cyclase type 7Homo sapiens (human)
magnesium ion bindingAdenylate cyclase type 2Homo sapiens (human)
adenylate cyclase activityAdenylate cyclase type 2Homo sapiens (human)
ATP bindingAdenylate cyclase type 2Homo sapiens (human)
adenylate cyclase bindingAdenylate cyclase type 2Homo sapiens (human)
manganese ion bindingAdenylate cyclase type 2Homo sapiens (human)
calmodulin bindingAdenylate cyclase type 1Homo sapiens (human)
ATP bindingAdenylate cyclase type 1Homo sapiens (human)
calcium- and calmodulin-responsive adenylate cyclase activityAdenylate cyclase type 1Homo sapiens (human)
metal ion bindingAdenylate cyclase type 1Homo sapiens (human)
adenylate cyclase activityAdenylate cyclase type 1Homo sapiens (human)
adenylate cyclase activityAdenylate cyclase type 4Homo sapiens (human)
protein kinase C bindingAdenylate cyclase type 4Homo sapiens (human)
protein bindingAdenylate cyclase type 4Homo sapiens (human)
ATP bindingAdenylate cyclase type 4Homo sapiens (human)
metal ion bindingAdenylate cyclase type 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (51)

Processvia Protein(s)Taxonomy
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
Golgi membraneD(2) dopamine receptorHomo sapiens (human)
acrosomal vesicleD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
ciliumD(2) dopamine receptorHomo sapiens (human)
lateral plasma membraneD(2) dopamine receptorHomo sapiens (human)
endocytic vesicleD(2) dopamine receptorHomo sapiens (human)
axonD(2) dopamine receptorHomo sapiens (human)
dendriteD(2) dopamine receptorHomo sapiens (human)
synaptic vesicle membraneD(2) dopamine receptorHomo sapiens (human)
sperm flagellumD(2) dopamine receptorHomo sapiens (human)
dendritic spineD(2) dopamine receptorHomo sapiens (human)
perikaryonD(2) dopamine receptorHomo sapiens (human)
axon terminusD(2) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(2) dopamine receptorHomo sapiens (human)
ciliary membraneD(2) dopamine receptorHomo sapiens (human)
non-motile ciliumD(2) dopamine receptorHomo sapiens (human)
dopaminergic synapseD(2) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(2) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(2) dopamine receptorHomo sapiens (human)
presynaptic membraneD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
cytoplasmAlpha-2C adrenergic receptorHomo sapiens (human)
endosomeAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
nucleusD(1A) dopamine receptorHomo sapiens (human)
endoplasmic reticulum membraneD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
ciliumD(1A) dopamine receptorHomo sapiens (human)
presynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
dendritic spineD(1A) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
ciliary membraneD(1A) dopamine receptorHomo sapiens (human)
non-motile ciliumD(1A) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(1A) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1B) dopamine receptorHomo sapiens (human)
ciliumD(1B) dopamine receptorHomo sapiens (human)
brush border membraneD(1B) dopamine receptorHomo sapiens (human)
synapseD(1B) dopamine receptorHomo sapiens (human)
ciliary membraneD(1B) dopamine receptorHomo sapiens (human)
non-motile ciliumD(1B) dopamine receptorHomo sapiens (human)
plasma membraneD(1B) dopamine receptorHomo sapiens (human)
Golgi membraneD(2) dopamine receptorHomo sapiens (human)
acrosomal vesicleD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
ciliumD(2) dopamine receptorHomo sapiens (human)
lateral plasma membraneD(2) dopamine receptorHomo sapiens (human)
endocytic vesicleD(2) dopamine receptorHomo sapiens (human)
axonD(2) dopamine receptorHomo sapiens (human)
dendriteD(2) dopamine receptorHomo sapiens (human)
synaptic vesicle membraneD(2) dopamine receptorHomo sapiens (human)
sperm flagellumD(2) dopamine receptorHomo sapiens (human)
dendritic spineD(2) dopamine receptorHomo sapiens (human)
perikaryonD(2) dopamine receptorHomo sapiens (human)
axon terminusD(2) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(2) dopamine receptorHomo sapiens (human)
ciliary membraneD(2) dopamine receptorHomo sapiens (human)
non-motile ciliumD(2) dopamine receptorHomo sapiens (human)
dopaminergic synapseD(2) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(2) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(2) dopamine receptorHomo sapiens (human)
presynaptic membraneD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
nucleusD(1A) dopamine receptorHomo sapiens (human)
endoplasmic reticulum membraneD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
ciliumD(1A) dopamine receptorHomo sapiens (human)
presynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
dendritic spineD(1A) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
ciliary membraneD(1A) dopamine receptorHomo sapiens (human)
non-motile ciliumD(1A) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(1A) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
plasma membraneAdenylate cyclase type 3Rattus norvegicus (Norway rat)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
cell surfaceSodium-dependent noradrenaline transporter Homo sapiens (human)
membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
presynaptic membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
axonSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneAdenylate cyclase type 8Rattus norvegicus (Norway rat)
plasma membraneAdenylate cyclase type 6Homo sapiens (human)
ciliumAdenylate cyclase type 6Homo sapiens (human)
membraneAdenylate cyclase type 6Homo sapiens (human)
stereociliumAdenylate cyclase type 6Homo sapiens (human)
plasma membraneAdenylate cyclase type 6Homo sapiens (human)
cytoplasmAdenylate cyclase type 3 Homo sapiens (human)
Golgi apparatusAdenylate cyclase type 3 Homo sapiens (human)
plasma membraneAdenylate cyclase type 3 Homo sapiens (human)
ciliumAdenylate cyclase type 3 Homo sapiens (human)
membraneAdenylate cyclase type 3 Homo sapiens (human)
ciliary membraneAdenylate cyclase type 3 Homo sapiens (human)
plasma membraneAdenylate cyclase type 3 Homo sapiens (human)
cytosolAdenylate cyclase type 9Homo sapiens (human)
plasma membraneAdenylate cyclase type 9Homo sapiens (human)
membraneAdenylate cyclase type 9Homo sapiens (human)
axonAdenylate cyclase type 9Homo sapiens (human)
dendriteAdenylate cyclase type 9Homo sapiens (human)
plasma membraneAdenylate cyclase type 9Homo sapiens (human)
plasma membraneAdenylate cyclase type 5Homo sapiens (human)
ciliumAdenylate cyclase type 5Homo sapiens (human)
membraneAdenylate cyclase type 5Homo sapiens (human)
plasma membraneAdenylate cyclase type 5Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
Golgi membraneD(2) dopamine receptorHomo sapiens (human)
acrosomal vesicleD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
ciliumD(2) dopamine receptorHomo sapiens (human)
lateral plasma membraneD(2) dopamine receptorHomo sapiens (human)
endocytic vesicleD(2) dopamine receptorHomo sapiens (human)
axonD(2) dopamine receptorHomo sapiens (human)
dendriteD(2) dopamine receptorHomo sapiens (human)
synaptic vesicle membraneD(2) dopamine receptorHomo sapiens (human)
sperm flagellumD(2) dopamine receptorHomo sapiens (human)
dendritic spineD(2) dopamine receptorHomo sapiens (human)
perikaryonD(2) dopamine receptorHomo sapiens (human)
axon terminusD(2) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(2) dopamine receptorHomo sapiens (human)
ciliary membraneD(2) dopamine receptorHomo sapiens (human)
non-motile ciliumD(2) dopamine receptorHomo sapiens (human)
dopaminergic synapseD(2) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(2) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(2) dopamine receptorHomo sapiens (human)
presynaptic membraneD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
Golgi membraneD(2) dopamine receptorBos taurus (cattle)
nucleusD(1A) dopamine receptorHomo sapiens (human)
endoplasmic reticulum membraneD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
ciliumD(1A) dopamine receptorHomo sapiens (human)
presynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
dendritic spineD(1A) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
ciliary membraneD(1A) dopamine receptorHomo sapiens (human)
non-motile ciliumD(1A) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(1A) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1B) dopamine receptorHomo sapiens (human)
ciliumD(1B) dopamine receptorHomo sapiens (human)
brush border membraneD(1B) dopamine receptorHomo sapiens (human)
synapseD(1B) dopamine receptorHomo sapiens (human)
ciliary membraneD(1B) dopamine receptorHomo sapiens (human)
non-motile ciliumD(1B) dopamine receptorHomo sapiens (human)
plasma membraneD(1B) dopamine receptorHomo sapiens (human)
actin cytoskeletonAdenylate cyclase type 8Homo sapiens (human)
plasma membraneAdenylate cyclase type 8Homo sapiens (human)
caveolaAdenylate cyclase type 8Homo sapiens (human)
clathrin-coated pitAdenylate cyclase type 8Homo sapiens (human)
postsynaptic densityAdenylate cyclase type 8Homo sapiens (human)
membraneAdenylate cyclase type 8Homo sapiens (human)
basolateral plasma membraneAdenylate cyclase type 8Homo sapiens (human)
apical plasma membraneAdenylate cyclase type 8Homo sapiens (human)
axonAdenylate cyclase type 8Homo sapiens (human)
dendriteAdenylate cyclase type 8Homo sapiens (human)
clathrin-coated vesicle membraneAdenylate cyclase type 8Homo sapiens (human)
neuronal cell body membraneAdenylate cyclase type 8Homo sapiens (human)
presynaptic membraneAdenylate cyclase type 8Homo sapiens (human)
plasma membrane raftAdenylate cyclase type 8Homo sapiens (human)
membrane raftAdenylate cyclase type 8Homo sapiens (human)
presynaptic active zoneAdenylate cyclase type 8Homo sapiens (human)
excitatory synapseAdenylate cyclase type 8Homo sapiens (human)
Schaffer collateral - CA1 synapseAdenylate cyclase type 8Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseAdenylate cyclase type 8Homo sapiens (human)
glutamatergic synapseAdenylate cyclase type 8Homo sapiens (human)
plasma membraneAdenylate cyclase type 8Homo sapiens (human)
plasma membraneAdenylate cyclase type 7Homo sapiens (human)
membraneAdenylate cyclase type 7Homo sapiens (human)
plasma membraneAdenylate cyclase type 7Homo sapiens (human)
cytoplasmAdenylate cyclase type 2Homo sapiens (human)
plasma membraneAdenylate cyclase type 2Homo sapiens (human)
membraneAdenylate cyclase type 2Homo sapiens (human)
dendriteAdenylate cyclase type 2Homo sapiens (human)
membrane raftAdenylate cyclase type 2Homo sapiens (human)
plasma membraneAdenylate cyclase type 2Homo sapiens (human)
cytoplasmAdenylate cyclase type 1Homo sapiens (human)
plasma membraneAdenylate cyclase type 1Homo sapiens (human)
membrane raftAdenylate cyclase type 1Homo sapiens (human)
extracellular exosomeAdenylate cyclase type 1Homo sapiens (human)
Schaffer collateral - CA1 synapseAdenylate cyclase type 1Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseAdenylate cyclase type 1Homo sapiens (human)
presynapseAdenylate cyclase type 1Homo sapiens (human)
postsynaptic density membraneAdenylate cyclase type 1Homo sapiens (human)
glutamatergic synapseAdenylate cyclase type 1Homo sapiens (human)
plasma membraneAdenylate cyclase type 1Homo sapiens (human)
cytoplasmAdenylate cyclase type 4Homo sapiens (human)
plasma membraneAdenylate cyclase type 4Homo sapiens (human)
membraneAdenylate cyclase type 4Homo sapiens (human)
dendriteAdenylate cyclase type 4Homo sapiens (human)
plasma membraneAdenylate cyclase type 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (184)

Assay IDTitleYearJournalArticle
AID55431Degradation rate constant for dopamine transporter by D1 receptor in nucleus accumbens was determined2003Journal of medicinal chemistry, May-08, Volume: 46, Issue:10
2002 Medicinal Chemistry Division Award address: monoamine transporters and opioid receptors. Targets for addiction therapy.
AID175491Compound was tested for its D-1 activity in rat caudate nuclei1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthesis and renal vasodilator activity of some dopamine agonist 1-aryl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diols: halogen and methyl analogues of fenoldopam.
AID1186140Displacement of [3H]spiperone from human dopamine D2 receptor expressed in HEK293 cell membranes by liquid scintillation counting based competition binding assay2014European journal of medicinal chemistry, Oct-06, Volume: 85Structural manipulation on the catecholic fragment of dopamine D(1) receptor agonist 1-phenyl-N-methyl-benzazepines.
AID189318Compound was tested for its CNS activity in vivo in SNx rats with 6-hydroxydopamine induced lesions after ip administration1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthesis and renal vasodilator activity of some dopamine agonist 1-aryl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diols: halogen and methyl analogues of fenoldopam.
AID57838Potency was expressed as the average maximum cumulative dose required to decrease renal vascular resistance by 15%1980Journal of medicinal chemistry, Sep, Volume: 23, Issue:9
Separation of potent central and renal dopamine agonist activity in substituted 6-chloro-2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepines.
AID1186143Displacement of [3H]ketanserin from human 5HT2A receptor expressed in HEK293 cell membranes by liquid scintillation counting based competition binding assay2014European journal of medicinal chemistry, Oct-06, Volume: 85Structural manipulation on the catecholic fragment of dopamine D(1) receptor agonist 1-phenyl-N-methyl-benzazepines.
AID1573449Agonist activity at human dopamine D1 receptor expressed in CHOK1 cells assessed as assessed as increase in beta-arrestin-2 recruitment after 60 mins by luminescence assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
AID1573450Agonist activity at human dopamine D1 receptor expressed in CHOK1 cells assessed as assessed as increase in beta-arrestin-2 recruitment after 60 mins by luminescence assay relative to control2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
AID64919In vitro affinity at mutant D2 receptor (S197A) in C6 (glioma) cell membranes.2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
CoMFA-based prediction of agonist affinities at recombinant wild type versus serine to alanine point mutated D2 dopamine receptors.
AID61220Formation of cAMP on Dopamine receptor D2 in vitro in rat intermediate lobe1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
(1R,3S)-1-(aminomethyl)-3,4-dihydro-5,6-dihydroxy-3-phenyl-1H-2-benzopyran: a potent and selective D1 agonist.
AID619751Displacement of [3H]SCH233930 from dopamine D5 receptor after 1.5 hrs by scintillation counting2011Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19
CNS and antimalarial activity of synthetic meridianin and psammopemmin analogs.
AID61658Degradation rate constant for dopamine transporter by D1 receptor in striatum was determined; no significant change2003Journal of medicinal chemistry, May-08, Volume: 46, Issue:10
2002 Medicinal Chemistry Division Award address: monoamine transporters and opioid receptors. Targets for addiction therapy.
AID729692Antagonist activity at dopamine D2 receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of [35S]GTPgammaS binding by scintillation proximity assay2013Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4
Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D(1), D(2) and serotonin 5-HT(1A) multi-action profile.
AID729709Antagonist activity at dopamine D1 receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of [35S]GTPgammaS binding by scintillation proximity assay2013Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4
Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D(1), D(2) and serotonin 5-HT(1A) multi-action profile.
AID1573447Agonist activity at human dopamine D1 receptor expressed in CHOK1 cells assessed as reversal of Ro 20-1724 mediated decrease in cAMP accumulation after 60 mins by luminescence assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
AID64790In vitro affinity at mutant D2 receptor (S194A) in C6 (glioma) cell membranes.2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
CoMFA-based prediction of agonist affinities at recombinant wild type versus serine to alanine point mutated D2 dopamine receptors.
AID1232265Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis2015Bioorganic & medicinal chemistry, Jul-15, Volume: 23, Issue:14
Cell-based and virtual fragment screening for adrenergic α2C receptor agonists.
AID729708Agonist activity at 5-HT1A receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of [35S]GTPgammaS binding by scintillation proximity assay2013Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4
Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D(1), D(2) and serotonin 5-HT(1A) multi-action profile.
AID175474Central dopaminergic activity was determined by testing compound for dopamine agonist activity mediated by adenylase cyclase in rat1980Journal of medicinal chemistry, Sep, Volume: 23, Issue:9
Separation of potent central and renal dopamine agonist activity in substituted 6-chloro-2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepines.
AID1186141Displacement of [3H]spiperone from human dopamine D3 receptor expressed in HEK293 cell membranes by liquid scintillation counting based competition binding assay2014European journal of medicinal chemistry, Oct-06, Volume: 85Structural manipulation on the catecholic fragment of dopamine D(1) receptor agonist 1-phenyl-N-methyl-benzazepines.
AID673217Antagonist activity at dopamine D1 receptor assessed as inhibition of [35S]GTPgammaS binding in cell-based assay relative to control2012Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15
Design, synthesis, and pharmacological evaluation of novel tetrahydroprotoberberine derivatives: selective inhibitors of dopamine D₁ receptor.
AID436906Displacement of [3H]8-OH-DPAT from 5HT1A receptor expressed in CHO cells at 10 uM by liquid scintillation counting2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
'Click' D(1) receptor agonists with a 5-HT(1A) receptor pharmacophore producing D(2) receptor activity.
AID61501Binding affinity was determined by measuring the ability to displace [125I]SCH-23982 from Dopamine receptor D1 in rat caudate (in vitro)1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
(1R,3S)-1-(aminomethyl)-3,4-dihydro-5,6-dihydroxy-3-phenyl-1H-2-benzopyran: a potent and selective D1 agonist.
AID252343Amount of cGMP level in rat neostriatal membranes after incubation at 10 uM2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Preparation and pharmacological characterization of trans-2-amino-5(6)-fluoro-6(5)-hydroxy-1-phenyl-2,3-dihydro-1H-indenes as D2-like dopamine receptor agonists.
AID673218Agonist activity at dopamine D1 receptor assessed as [35S]GTPgammaS binding in cell-based assay2012Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15
Design, synthesis, and pharmacological evaluation of novel tetrahydroprotoberberine derivatives: selective inhibitors of dopamine D₁ receptor.
AID252345Amount of cGMP level in rat neostriatal membranes after incubation at 1.0 uM2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Preparation and pharmacological characterization of trans-2-amino-5(6)-fluoro-6(5)-hydroxy-1-phenyl-2,3-dihydro-1H-indenes as D2-like dopamine receptor agonists.
AID59135Effective Dose (ED15) required to decrease renal vascular resistance by 15% in anesthetized dogs administered intravenously1980Journal of medicinal chemistry, Sep, Volume: 23, Issue:9
Separation of potent central and renal dopamine agonist activity in substituted 6-chloro-2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepines.
AID64917In vitro affinity at mutant D2 receptor (S194A) in C6 (glioma) cell membranes.2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
CoMFA-based prediction of agonist affinities at recombinant wild type versus serine to alanine point mutated D2 dopamine receptors.
AID673216Antagonist activity at dopamine D1 receptor assessed as inhibition of [35S]GTPgammaS binding in cell-based assay2012Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15
Design, synthesis, and pharmacological evaluation of novel tetrahydroprotoberberine derivatives: selective inhibitors of dopamine D₁ receptor.
AID42812Percent of maximal effect of 125 uM Dopamine in the adenylate cyclase assay.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
trans-hexahydroindolo[4,3-ab]phenanthridines ("benzergolines"), the first structural class of potent and selective dopamine D1 receptor agonists lacking a catechol group.
AID61249Displacement of [3H]YM-09151-2 (60 pm) from dopamine receptor D2 in crude membrane fraction of rat brain corpus striatum1992Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8
Stereoisomeric probes for the D1 dopamine receptor: synthesis and characterization of R-(+) and S-(-) enantiomers of 3-allyl-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine and its 6-bromo analogue.
AID729710Agonist activity at dopamine D1 receptor (unknown origin) expressed in HEK293 cells assessed as stimulation of [35S]GTPgammaS binding by scintillation proximity assay2013Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4
Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D(1), D(2) and serotonin 5-HT(1A) multi-action profile.
AID63043Percent intrinsic activity as formation of cAMP on Dopamine receptor D1 in vitro in carp retina1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
(1R,3S)-1-(aminomethyl)-3,4-dihydro-5,6-dihydroxy-3-phenyl-1H-2-benzopyran: a potent and selective D1 agonist.
AID436903Displacement of [3H]spiperone from dopamine D2 receptor expressed in HEK293 cells at 10 uM by liquid scintillation counting2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
'Click' D(1) receptor agonists with a 5-HT(1A) receptor pharmacophore producing D(2) receptor activity.
AID42815In vitro percent maximal stimulation relative to dopamine (125 uM) in bovine retina1993Journal of medicinal chemistry, Apr-16, Volume: 36, Issue:8
Structure-activity relationships in the trans-hexahydroindolo[4,3-ab]phenanthridine ("benzergoline") series. 2. Resolution, absolute configuration, and dopaminergic activity of the selective D1 agonist CY 208-243 and its implication for an "extended rotam
AID189189Central dopaminergic activity was determined by testing compound for its ability to produce contralateral rotation in lesioned rat after intracerebrally administration1980Journal of medicinal chemistry, Sep, Volume: 23, Issue:9
Separation of potent central and renal dopamine agonist activity in substituted 6-chloro-2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepines.
AID1542816Agonist activity at D1 receptor (unknown origin) expressed in CHOK1 cells assessed as increase in cAMP accumulation measured after 30 mins2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Chemical synthesis, microbial transformation and biological evaluation of tetrahydroprotoberberines as dopamine D1/D2 receptor ligands.
AID232949D1 selectivity was defined as IC50(D2)/IC50(D1)1992Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8
Stereoisomeric probes for the D1 dopamine receptor: synthesis and characterization of R-(+) and S-(-) enantiomers of 3-allyl-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine and its 6-bromo analogue.
AID34166In vitro potency against adenylate cyclase in bovine retina1993Journal of medicinal chemistry, Apr-16, Volume: 36, Issue:8
Structure-activity relationships in the trans-hexahydroindolo[4,3-ab]phenanthridine ("benzergoline") series. 2. Resolution, absolute configuration, and dopaminergic activity of the selective D1 agonist CY 208-243 and its implication for an "extended rotam
AID61659Half life of recovery for dopamine transporter by Dopamine receptor D1 in striatum was determined; no significant change2003Journal of medicinal chemistry, May-08, Volume: 46, Issue:10
2002 Medicinal Chemistry Division Award address: monoamine transporters and opioid receptors. Targets for addiction therapy.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID436910Agonist activity at dopamine D1 receptor expressed in HEK293 cells by by [35S]GTPgammaS binding assay2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
'Click' D(1) receptor agonists with a 5-HT(1A) receptor pharmacophore producing D(2) receptor activity.
AID61015Displacement of [3H]-SCH- 23390 (0.3 nM) from dopamine receptor D1 in crude membrane fraction of rat brain corpus striatum1992Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8
Stereoisomeric probes for the D1 dopamine receptor: synthesis and characterization of R-(+) and S-(-) enantiomers of 3-allyl-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine and its 6-bromo analogue.
AID252344Amount of cGMP level in rat neostriatal membranes after incubation at 0.1 uM2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Preparation and pharmacological characterization of trans-2-amino-5(6)-fluoro-6(5)-hydroxy-1-phenyl-2,3-dihydro-1H-indenes as D2-like dopamine receptor agonists.
AID65250Binding affinity was determined by measuring the ability to displace [125I]N-(p-aminophenethyl)-spiroperidol from Dopamine receptor D2 in rat caudate (in vitro)1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
(1R,3S)-1-(aminomethyl)-3,4-dihydro-5,6-dihydroxy-3-phenyl-1H-2-benzopyran: a potent and selective D1 agonist.
AID63042Formation of cAMP on Dopamine receptor D1 in vitro in carp retina1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
(1R,3S)-1-(aminomethyl)-3,4-dihydro-5,6-dihydroxy-3-phenyl-1H-2-benzopyran: a potent and selective D1 agonist.
AID189190Central dopaminergic activity was determined by testing compound for its ability to produce contralateral rotation in lesioned rat after ip administration1980Journal of medicinal chemistry, Sep, Volume: 23, Issue:9
Separation of potent central and renal dopamine agonist activity in substituted 6-chloro-2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepines.
AID436899Displacement of [3H]SCH23390 from dopamine D1 receptor expressed in HEK293 cells by liquid scintillation counting2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
'Click' D(1) receptor agonists with a 5-HT(1A) receptor pharmacophore producing D(2) receptor activity.
AID61752Maximum percent decrease in renal vascular resistance.1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthesis and renal vasodilator activity of some dopamine agonist 1-aryl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diols: halogen and methyl analogues of fenoldopam.
AID64925In vitro affinity at wild type Dopamine receptor D2 on C6 (glioma) cell membranes.2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
CoMFA-based prediction of agonist affinities at recombinant wild type versus serine to alanine point mutated D2 dopamine receptors.
AID61666Degradation rate constant for dopamine transporter by D1 receptor in nucleus accumbens was determined2003Journal of medicinal chemistry, May-08, Volume: 46, Issue:10
2002 Medicinal Chemistry Division Award address: monoamine transporters and opioid receptors. Targets for addiction therapy.
AID1186139Displacement of [3H]SCH23390 from human dopamine D1 receptor expressed in HEK293 cell membranes by liquid scintillation counting based competition binding assay2014European journal of medicinal chemistry, Oct-06, Volume: 85Structural manipulation on the catecholic fragment of dopamine D(1) receptor agonist 1-phenyl-N-methyl-benzazepines.
AID42814Compound was evaluated for its potency to Dopamine D2 stimulating effect in the adenylate cyclase assay.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
trans-hexahydroindolo[4,3-ab]phenanthridines ("benzergolines"), the first structural class of potent and selective dopamine D1 receptor agonists lacking a catechol group.
AID673219Agonist activity at dopamine D1 receptor assessed as [35S]GTPgammaS binding in cell-based assay relative to control2012Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15
Design, synthesis, and pharmacological evaluation of novel tetrahydroprotoberberine derivatives: selective inhibitors of dopamine D₁ receptor.
AID59139Renal vasodilator activity was determined in anesthetized dogs1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthesis and renal vasodilator activity of some dopamine agonist 1-aryl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diols: halogen and methyl analogues of fenoldopam.
AID234666Renal vasodilator activity was measured between ED20, measure of mean arterial blood pressure (MABP) test, and ED15 RVR.1980Journal of medicinal chemistry, Sep, Volume: 23, Issue:9
Separation of potent central and renal dopamine agonist activity in substituted 6-chloro-2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepines.
AID189317Compound was tested for its CNS activity in vivo in SNx rats with 6-hydroxydopamine induced lesions after ic administration1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthesis and renal vasodilator activity of some dopamine agonist 1-aryl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diols: halogen and methyl analogues of fenoldopam.
AID55432Half life of recovery for dopamine transporter by D1 receptor in nucleus accumbens was determined2003Journal of medicinal chemistry, May-08, Volume: 46, Issue:10
2002 Medicinal Chemistry Division Award address: monoamine transporters and opioid receptors. Targets for addiction therapy.
AID1573448Agonist activity at human dopamine D1 receptor expressed in CHOK1 cells assessed as reversal of Ro 20-1724 mediated decrease in cAMP accumulation after 60 mins by luminescence assay relative to control2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
AID59282cardiovascular activity was determined in anesthetized dogs.(Heart rate )1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthesis and renal vasodilator activity of some dopamine agonist 1-aryl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diols: halogen and methyl analogues of fenoldopam.
AID173831Percent of maximal inhibition by change of S2/S1 versus control at 1 uM for the cetylcholine (ACh) release as a model for Dopamine D2 receptor activation.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
trans-hexahydroindolo[4,3-ab]phenanthridines ("benzergolines"), the first structural class of potent and selective dopamine D1 receptor agonists lacking a catechol group.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID436900Agonist activity at dopamine D1 receptor2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
'Click' D(1) receptor agonists with a 5-HT(1A) receptor pharmacophore producing D(2) receptor activity.
AID192840Tested in vitro for percent maximal inhibition in rat striatal slices (% of control) expressed as change of S1/S2 versus control at 1 uM1993Journal of medicinal chemistry, Apr-16, Volume: 36, Issue:8
Structure-activity relationships in the trans-hexahydroindolo[4,3-ab]phenanthridine ("benzergoline") series. 2. Resolution, absolute configuration, and dopaminergic activity of the selective D1 agonist CY 208-243 and its implication for an "extended rotam
AID1232267Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis relative to UK143042015Bioorganic & medicinal chemistry, Jul-15, Volume: 23, Issue:14
Cell-based and virtual fragment screening for adrenergic α2C receptor agonists.
AID59283cardiovascular activity was determined in anesthetized dogs.(Mean arterial blood pressure)1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthesis and renal vasodilator activity of some dopamine agonist 1-aryl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diols: halogen and methyl analogues of fenoldopam.
AID1168797Agonist activity at D1 receptor (unknown origin) after 40 mins by [35S]GTP-gammaS binding assay2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Design, synthesis and evaluation of benzo[a]thieno[3,2-g]quinolizines as novel l-SPD derivatives possessing dopamine D1, D2 and serotonin 5-HT1A multiple action profiles.
AID1232266Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis2015Bioorganic & medicinal chemistry, Jul-15, Volume: 23, Issue:14
Cell-based and virtual fragment screening for adrenergic α2C receptor agonists.
AID234667Renal vasodilator activity was measured between ED30, measure in iliac vascular resistance (IVR) test, and ED15 RVR1980Journal of medicinal chemistry, Sep, Volume: 23, Issue:9
Separation of potent central and renal dopamine agonist activity in substituted 6-chloro-2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepines.
AID436902Binding affinity to dopamine D2 receptor2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
'Click' D(1) receptor agonists with a 5-HT(1A) receptor pharmacophore producing D(2) receptor activity.
AID1186142Displacement of [3H]8-OH-DPAT from rat 5HT1A receptor expressed in CHO cell membranes by liquid scintillation counting based competition binding assay2014European journal of medicinal chemistry, Oct-06, Volume: 85Structural manipulation on the catecholic fragment of dopamine D(1) receptor agonist 1-phenyl-N-methyl-benzazepines.
AID59296Effective dose against Iliac vascular resistance (IVR)1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthesis and renal vasodilator activity of some dopamine agonist 1-aryl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diols: halogen and methyl analogues of fenoldopam.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1345718Human D1 receptor (Dopamine receptors)1994The Journal of biological chemistry, Nov-11, Volume: 269, Issue:45
High agonist-independent activity is a distinguishing feature of the dopamine D1B receptor subtype.
AID1345879Human D5 receptor (Dopamine receptors)1991Nature, Apr-18, Volume: 350, Issue:6319
Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
AID1345718Human D1 receptor (Dopamine receptors)1991Nature, Apr-18, Volume: 350, Issue:6319
Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1802076D1R Functional Assay from Article 10.1111/cbdd.12796: \\Functional reversal of (-)-Stepholidine analogues by replacement of benzazepine substructure using the ring-expansion strategy.\\2016Chemical biology & drug design, 10, Volume: 88, Issue:4
Functional reversal of (-)-Stepholidine analogues by replacement of benzazepine substructure using the ring-expansion strategy.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID34440Tested for ability to stimulate dopamine sensitive adenylate cyclase in rat caudate homogenate1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Absolute stereochemistry and dopaminergic activity of enantiomers of 2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine.
AID63209The compound was evaluated for the dissociation constant for inhibiting the binding of [3H]-SCH- 23390 at Dopamine receptor D11991Journal of medicinal chemistry, Dec, Volume: 34, Issue:12
(+/-)-3-Allyl-6-bromo-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3- benzazepin, a new high-affinity D1 dopamine receptor ligand: synthesis and structure-activity relationship.
AID186061Compound was tested for maximum response, the percent of cyclic AMP induced by 1 x 10 E-5 M dopamine1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Absolute stereochemistry and dopaminergic activity of enantiomers of 2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine.
AID62878Tested for Dopamine receptor activity by the inhibition against spiroperidol binding to rat caudate tissue.1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Absolute stereochemistry and dopaminergic activity of enantiomers of 2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine.
AID61066The compound was evaluated for the binding affinity towards Dopamine receptor D2 at low affinity state1991Journal of medicinal chemistry, Dec, Volume: 34, Issue:12
(+/-)-3-Allyl-6-bromo-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3- benzazepin, a new high-affinity D1 dopamine receptor ligand: synthesis and structure-activity relationship.
AID59132Compound was tested for its renal vasodilator activity in dogs.1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Absolute stereochemistry and dopaminergic activity of enantiomers of 2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine.
AID189177Ability to induce contralateral rotations in rats having lesions in the substantia nigra.1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Absolute stereochemistry and dopaminergic activity of enantiomers of 2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine.
AID61064The compound was evaluated for the binding affinity towards Dopamine receptor D2 at high affinity state1991Journal of medicinal chemistry, Dec, Volume: 34, Issue:12
(+/-)-3-Allyl-6-bromo-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3- benzazepin, a new high-affinity D1 dopamine receptor ligand: synthesis and structure-activity relationship.
AID60956Renal vascular resistance (RVR) in dog was determined1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Absolute stereochemistry and dopaminergic activity of enantiomers of 2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID62764Intrinsic activity relative to dopamine for human Dopamine receptor D21995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
(5aR,11bS)-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-azacyclopent-1- ena[c]-phenanthrene-9,10-diol (A-86929): a potent and selective dopamine D1 agonist that maintains behavioral efficacy following repeated administration and characterization of its diac
AID63211Adenylate cyclase assay carried out in LTK cells transfected with human Dopamine receptor D11995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
(5aR,11bS)-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-azacyclopent-1- ena[c]-phenanthrene-9,10-diol (A-86929): a potent and selective dopamine D1 agonist that maintains behavioral efficacy following repeated administration and characterization of its diac
AID61513Binding affinity for dopamine receptor D11991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Synthesis and pharmacological evaluation of 1-(aminomethyl)-3,4-dihydro-5-hydroxy-1H-2-benzopyrans as dopamine D1 selective ligands.
AID232939Binding selectivity against D2/D1 receptor.1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Substituted hexahydrobenzo[f]thieno[c]quinolines as dopamine D1-selective agonists: synthesis and biological evaluation in vitro and in vivo.
AID61351Binding affinity to the dopamine receptor D1 by displacing [3H]-SCH- 23390 radio-ligand in rat striatal membranes by using radioligand competition assay.1995Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13
Synthesis and evaluation of 6,7-dihydroxy-2,3,4,8,9,13b-hexahydro-1H- benzo[6,7]cyclohepta[1,2,3-ef][3]benzazepine, 6,7-dihydroxy- 1,2,3,4,8,12b-hexahydroanthr[10,4a,4-cd]azepine, and 10-(aminomethyl)-9,10- dihydro-1,2-dihydroxyanthracene as conformationa
AID1063794Displacement of [3H]SCH23390 from dopamine D5 receptor (unknown origin)2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds.
AID34290In vitro inhibition of dopamine stimulated adenylate cyclase; na = 'not applicable'1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Synthesis and pharmacological evaluation of 1-(aminomethyl)-3,4-dihydro-5-hydroxy-1H-2-benzopyrans as dopamine D1 selective ligands.
AID63041Concentration required to inhibit 50% dopamine receptor D1 activity using cell free homogenate of carp retina1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and dopaminergic activity of 3-substituted 1-(aminomethyl)-3,4-dihydro-5,6-dihydroxy-1H-2-benzopyrans: characterization of an auxiliary binding region in the D1 receptor.
AID62005Binding affinity against dopamine receptor D2 by using [3H]spiperone as radioligand in caudate-putamen of monkey1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Fluorescent probes for dopamine receptors: synthesis and characterization of fluorescein and 7-nitrobenz-2-oxa-1,3-diazol-4-yl conjugates of D-1 and D-2 receptor ligands.
AID227611Intrinsic activity measured relative to dopamine on D1C(R) receptor1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and dopaminergic activity of 3-substituted 1-(aminomethyl)-3,4-dihydro-5,6-dihydroxy-1H-2-benzopyrans: characterization of an auxiliary binding region in the D1 receptor.
AID169003Compound was tested for the net contralateral rotations in rats, 2 hr after sc administration of 0.43 umol/kg dopamine agonist; Activity expressed as net contralateral rotations / 2 hr1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Synthesis and pharmacological evaluation of 1-(aminomethyl)-3,4-dihydro-5-hydroxy-1H-2-benzopyrans as dopamine D1 selective ligands.
AID63344Binding affinity against cloned human Dopamine receptor D1 using [125I]-SCH 23982 as radioligand transfected in HEK cells1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
(5aR,11bS)-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-azacyclopent-1- ena[c]-phenanthrene-9,10-diol (A-86929): a potent and selective dopamine D1 agonist that maintains behavioral efficacy following repeated administration and characterization of its diac
AID64782Binding affinity of compound towards Dopamine receptor D2 was determined in rat striatal homogenate using [3H]- spiperone as radioligand; Not tested1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore.
AID1664376Agonist activity at dopamine D1 receptor (unknown origin)2020Bioorganic & medicinal chemistry letters, 08-15, Volume: 30, Issue:16
Synthesis and dopamine receptor pharmacological evaluations on ring C ortho halogenated 1-phenylbenzazepines.
AID63338Intrinsic activity relative to dopamine for human Dopamine receptor D11995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
(5aR,11bS)-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-azacyclopent-1- ena[c]-phenanthrene-9,10-diol (A-86929): a potent and selective dopamine D1 agonist that maintains behavioral efficacy following repeated administration and characterization of its diac
AID1137629Agonist activity at dopamine D1 receptor (unknown origin)2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent c-Met/ALK Multikinase Inhibitory Activities.
AID34601Effective dose required to stimulate Adenylate cyclase1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Conformational analysis and structure-activity relationships of selective dopamine D-1 receptor agonists and antagonists of the benzazepine series.
AID61865Equilibrium dissociation constant against recombinant Dopamine receptor D1A expressed in COS7 cells1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
Comparative molecular field analysis-based prediction of drug affinities at recombinant D1A dopamine receptors.
AID61858Ability to stimulate the Dopamine receptor D1 like was assayed by measuring cAMP production in cell free homogenates of goldfish retinal tissue1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Substituted hexahydrobenzo[f]thieno[c]quinolines as dopamine D1-selective agonists: synthesis and biological evaluation in vitro and in vivo.
AID61494Binding affinity using [125 I] SCH 23982 radioligand competitive binding assay on dopamine receptor D11991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and dopaminergic activity of 3-substituted 1-(aminomethyl)-3,4-dihydro-5,6-dihydroxy-1H-2-benzopyrans: characterization of an auxiliary binding region in the D1 receptor.
AID61344Inhibitory activity against Dopamine receptor D1 by displacement of [3H]fenoldopam from homogenated rat striatum1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis, conformation, and dopaminergic activity of 5,6-ethano-bridged derivatives of selective dopaminergic 3-benzazepines.
AID227613Intrinsic activity measured relative to dopamine on D1C(S) receptor1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and dopaminergic activity of 3-substituted 1-(aminomethyl)-3,4-dihydro-5,6-dihydroxy-1H-2-benzopyrans: characterization of an auxiliary binding region in the D1 receptor.
AID169000Compound was tested for the net contralateral rotations in rats 2 hr after administration of 1.7 umol/kg, predosed with SCH-23390 (0.05 umol/kg sc), 40 min prior to injection of test compound; Activity expressed as net contralateral rotations / 2ho1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Synthesis and pharmacological evaluation of 1-(aminomethyl)-3,4-dihydro-5-hydroxy-1H-2-benzopyrans as dopamine D1 selective ligands.
AID88009Displacement of [3H](-)-trans-H2-PAT from histamine H2 PAT binding site by competition binding assay.1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Synthesis, evaluation, and comparative molecular field analysis of 1-phenyl-3-amino-1,2,3,4-tetrahydronaphthalenes as ligands for histamine H(1) receptors.
AID64784Binding affinity towards Dopamine receptor D2 by displacing [3H]spiperone radio-ligand in rat striatal membranes by using radioligand competition assay.1995Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13
Synthesis and evaluation of 6,7-dihydroxy-2,3,4,8,9,13b-hexahydro-1H- benzo[6,7]cyclohepta[1,2,3-ef][3]benzazepine, 6,7-dihydroxy- 1,2,3,4,8,12b-hexahydroanthr[10,4a,4-cd]azepine, and 10-(aminomethyl)-9,10- dihydro-1,2-dihydroxyanthracene as conformationa
AID34592Compound was tested for the adenylate cyclase stimulation1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
A study on the contribution of the 1-phenyl substituent to the molecular electrostatic potentials of some benzazepines in relation to selective dopamine D-1 receptor activity.
AID227610Intrinsic activity relative to dopamine at D-2 receptor; No data.1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and dopaminergic activity of 3-substituted 1-(aminomethyl)-3,4-dihydro-5,6-dihydroxy-1H-2-benzopyrans: characterization of an auxiliary binding region in the D1 receptor.
AID61820Binding affinity against Dopamine receptor D1 in rat radioligand1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Conformational analysis and structure-activity relationships of selective dopamine D-1 receptor agonists and antagonists of the benzazepine series.
AID61867log(1/Kd) value against recombinant Dopamine receptor D1A expressed in COS7 cell1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
Comparative molecular field analysis-based prediction of drug affinities at recombinant D1A dopamine receptors.
AID63040Affinity towards Dopamine receptor D11998Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22
CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
AID63370Displacement of [3H]- #NAME? from binding Dopamine receptor D1 in rat striatum1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist.
AID232940Binding selectivity against alpha-2/D1 receptor.1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Substituted hexahydrobenzo[f]thieno[c]quinolines as dopamine D1-selective agonists: synthesis and biological evaluation in vitro and in vivo.
AID228912Tested for dopamine-sensitive adenylate cyclase stimulation expressed as ED501987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis, conformation, and dopaminergic activity of 5,6-ethano-bridged derivatives of selective dopaminergic 3-benzazepines.
AID232949D1 selectivity was defined as IC50(D2)/IC50(D1)1992Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8
Stereoisomeric probes for the D1 dopamine receptor: synthesis and characterization of R-(+) and S-(-) enantiomers of 3-allyl-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine and its 6-bromo analogue.
AID62184Inhibitory activity against Dopamine receptor D2 by displacement of [3H]spiroperidol from bovine pituitary1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis, conformation, and dopaminergic activity of 5,6-ethano-bridged derivatives of selective dopaminergic 3-benzazepines.
AID319300Intrinsic activity at human recombinant dopamine D1 receptor expressed in CHO cells assessed as stimulation of cAMP production2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
A novel synthesis and pharmacological evaluation of a potential dopamine D1/D2 agonist: 1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diol.
AID64301In vitro binding affinity against Dopamine receptor D2 like from rat caudate membrane using [3H]-spiperone as radioligand1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Substituted hexahydrobenzo[f]thieno[c]quinolines as dopamine D1-selective agonists: synthesis and biological evaluation in vitro and in vivo.
AID34316Percentage maximum stimulation adenylate cyclase was measured versus DA1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist.
AID37373In vitro binding affinity against adrenergic Alpha-2 adrenergic receptor from rat cortical membrane using [3H]rauwolscine as radioligand1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Substituted hexahydrobenzo[f]thieno[c]quinolines as dopamine D1-selective agonists: synthesis and biological evaluation in vitro and in vivo.
AID61012Tested for its affinity towards Dopamine receptor D1 in rat striatal membrane1994Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15
Dopaminergic benzo[a]phenanthridines: resolution and pharmacological evaluation of the enantiomers of dihydrexidine, the full efficacy D1 dopamine receptor agonist.
AID61862In vitro binding affinity against Dopamine receptor D1 like from rat caudate membrane using [125I]-SCH as radioligand1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Substituted hexahydrobenzo[f]thieno[c]quinolines as dopamine D1-selective agonists: synthesis and biological evaluation in vitro and in vivo.
AID319298Agonist activity at human recombinant dopamine D1 receptor expressed in CHO cells assessed as stimulation of cAMP production2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
A novel synthesis and pharmacological evaluation of a potential dopamine D1/D2 agonist: 1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diol.
AID319299Agonist activity at human dopamine D2 receptor expressed in CHO cells assessed as inhibition of forskolin-stimulated cAMP production2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
A novel synthesis and pharmacological evaluation of a potential dopamine D1/D2 agonist: 1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diol.
AID1664377Agonist activity at dopamine D5 receptor (unknown origin)2020Bioorganic & medicinal chemistry letters, 08-15, Volume: 30, Issue:16
Synthesis and dopamine receptor pharmacological evaluations on ring C ortho halogenated 1-phenylbenzazepines.
AID63227Affinity towards Dopamine receptor D21998Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22
CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
AID177567Ability to produce robust rotation in the lesioned rat after subcutaneous administration1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
(5aR,11bS)-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-azacyclopent-1- ena[c]-phenanthrene-9,10-diol (A-86929): a potent and selective dopamine D1 agonist that maintains behavioral efficacy following repeated administration and characterization of its diac
AID61859Intrinsic activity is the magnitude of response for stimulation of Dopamine receptor D1 like expressed as percent relative to the dopamine1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
Substituted hexahydrobenzo[f]thieno[c]quinolines as dopamine D1-selective agonists: synthesis and biological evaluation in vitro and in vivo.
AID65110Binding affinity using [3H]-spiperone radioligand competitive binding assay against dopamine receptor D21991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and dopaminergic activity of 3-substituted 1-(aminomethyl)-3,4-dihydro-5,6-dihydroxy-1H-2-benzopyrans: characterization of an auxiliary binding region in the D1 receptor.
AID61219Concentration required to inhibit 50% dopamine receptor D2 in a cell free homogenate of intermediate lobe of pituitary gland1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and dopaminergic activity of 3-substituted 1-(aminomethyl)-3,4-dihydro-5,6-dihydroxy-1H-2-benzopyrans: characterization of an auxiliary binding region in the D1 receptor.
AID34598Effective concentration required to stimulate Adenylate cyclase1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Conformational analysis and structure-activity relationships of selective dopamine D-1 receptor agonists and antagonists of the benzazepine series.
AID63038Binding affinity against dopamine receptor D1 by using [3H]-SCH- 23390 as radioligand in caudate-putamen of monkey1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Fluorescent probes for dopamine receptors: synthesis and characterization of fluorescein and 7-nitrobenz-2-oxa-1,3-diazol-4-yl conjugates of D-1 and D-2 receptor ligands.
AID64282Displacement of [3H]- -spiperone from Dopamine receptor D2 in rat striatum1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist.
AID61015Displacement of [3H]-SCH- 23390 (0.3 nM) from dopamine receptor D1 in crude membrane fraction of rat brain corpus striatum1992Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8
Stereoisomeric probes for the D1 dopamine receptor: synthesis and characterization of R-(+) and S-(-) enantiomers of 3-allyl-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine and its 6-bromo analogue.
AID62748Adenylate cyclase assay carried out in LTK cells transfected with human Dopamine receptor D21995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
(5aR,11bS)-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-azacyclopent-1- ena[c]-phenanthrene-9,10-diol (A-86929): a potent and selective dopamine D1 agonist that maintains behavioral efficacy following repeated administration and characterization of its diac
AID34315Stimulation of Adenylate cyclase from rat striatal membranes1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist.
AID228504Tested for dopamine-sensitive adenylate cyclase stimulation expressed as %DA stimulation at 10 uM1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis, conformation, and dopaminergic activity of 5,6-ethano-bridged derivatives of selective dopaminergic 3-benzazepines.
AID61347Binding affinity of compound towards dopamine receptor D1 was determined in rat striatal homogenate using [3H]SCH-23390 as radioligand1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore.
AID62918Binding affinity against cloned human Dopamine receptor D2 using [3H]spiperone as radioligand transfected in HEK cells1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
(5aR,11bS)-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-azacyclopent-1- ena[c]-phenanthrene-9,10-diol (A-86929): a potent and selective dopamine D1 agonist that maintains behavioral efficacy following repeated administration and characterization of its diac
AID63375Concentration required to inhibit 50% dopamine receptor D1 using cell free homogenate of rat striatum1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and dopaminergic activity of 3-substituted 1-(aminomethyl)-3,4-dihydro-5,6-dihydroxy-1H-2-benzopyrans: characterization of an auxiliary binding region in the D1 receptor.
AID169002Compound was tested for the net contralateral rotations in rats 2 hr after sc administration of 1.7 umol/kg dopamine agonist; Activity expressed as net contralateral rotations / 2 hr1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Synthesis and pharmacological evaluation of 1-(aminomethyl)-3,4-dihydro-5-hydroxy-1H-2-benzopyrans as dopamine D1 selective ligands.
AID235513Selectivity was calculated as ratio (D-1/D-2 or D-2/D1) of the corresponding Ki values of the compound1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Fluorescent probes for dopamine receptors: synthesis and characterization of fluorescein and 7-nitrobenz-2-oxa-1,3-diazol-4-yl conjugates of D-1 and D-2 receptor ligands.
AID61249Displacement of [3H]YM-09151-2 (60 pm) from dopamine receptor D2 in crude membrane fraction of rat brain corpus striatum1992Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8
Stereoisomeric probes for the D1 dopamine receptor: synthesis and characterization of R-(+) and S-(-) enantiomers of 3-allyl-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine and its 6-bromo analogue.
AID65429Binding affinity for dopamine receptor D21991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Synthesis and pharmacological evaluation of 1-(aminomethyl)-3,4-dihydro-5-hydroxy-1H-2-benzopyrans as dopamine D1 selective ligands.
AID61996Low-affinity agonist dissociation constant against striatal Dopamine receptor D1A1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
Comparative molecular field analysis-based prediction of drug affinities at recombinant D1A dopamine receptors.
AID233473Hill slope was determined for the compound in D1 receptor binding assay1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore.
AID64315Equilibrium dissociation constant against recombinant Dopamine receptor D2A expressed in COS7 cells1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
Comparative molecular field analysis-based prediction of drug affinities at recombinant D1A dopamine receptors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,991)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990365 (18.33)18.7374
1990's955 (47.97)18.2507
2000's382 (19.19)29.6817
2010's242 (12.15)24.3611
2020's47 (2.36)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 7.00

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index7.00 (24.57)
Research Supply Index7.62 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (7.00)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials29 (1.44%)5.53%
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews25 (1.24%)6.00%
Reviews0 (0.00%)6.00%
Reviews0 (0.00%)6.00%
Case Studies1 (0.05%)4.05%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other1,957 (97.27%)84.16%
Other12 (100.00%)84.16%
Other20 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]